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9ABSTRACT
Migraine is a highly prevalent disease, 
and despite several important break-
throughs there are still a many ques-
tions unanswered in the clinical, ge-
netic and pathophysiological aspects 
of migraine research. Migraine has 
been linked to several other diseases 
such as epilepsy and stroke, but there 
are still unsolved issues concerning 
the true nature of these associations. 
Three genes predisposing to hemiple-
gic migraine and several loci associ-
ated to migraine have been identified, 
but so far no genes responsible for 
common forms of migraine have been 
recognized. Triptans have provided an 
important step in migraine treatment, 
but their usefulness in rare forms of 
migraine have been controversial. 
 The Finnish Migraine Gene 
Project (FMGP) includes more than 
1600 families and 7500 individuals. 
We evaluated comorbidity from 1000 
consecutive subjects in the FMGP. To 
search for novel loci, we performed a 
genome-wide linkage scan in 36 fami-
lies with high prevalences of migraine 
with visual aura. We collected 76 sub-
jects from the FMGP who suffer from 
hemiplegic migraine and have used 
triptans. Finally, to study possible links 
between stroke and migraine we eval-
uated the prevalence of migraine in 
subjects with cervical artery dissection 
(CAD) and healthy controls.
 Migraine was associated with 
increased prevalence of allergy, hypo-
tension and psychiatric diseases. Addi-
tionally, men suffering from migraine 
with aura had increased prevalence 
of epilepsy and stroke. Further evi-
dence of association between migraine 
and epilepsy was found in our linkage 
study. The parametric two-point link-
age analysis showed significant evi-
dence of linkage between migraine 
aura and a locus on 9q21-q22. Interest-
ingly, the same locus has been associ-
ated with occipitotemporal epilepsy. 
CAD seems to be a migraine risk fac-
tor, and therefore a link between stroke 
and migraine. Notably, CAD seems to 
alleviate migraine activity further in-
dicating the association between these 
two conditions. Despite the contraindi-
cations of triptans, it seems that they 
are safe and effective in the abortive 
treatment of hemiplegic migraine.             
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INTRODUCTION
Migraine is a painful and disabling dis-
ease. It is highly prevalent worldwide 
among people of working age and there-
fore causes a significant economical bur-
den and a remarkable decrease in quality 
of life. In recent decades there has been 
great success in migraine research, but 
still there is an enormous need for better 
treatments and lack of understanding of 
the mechanisms and genetic background 
of the disease. Studying the comorbidi-
ty of migraine is one possible method to 
better elucidate such mechanisms. Pre-
viously migraine has been associated 
with several conditions, such as immu-
nological and psychiatric disorders, and 
importantly to two other brain diseases, 
epilepsy and ischemic stroke.          
 For several decades the lead-
ing theory of migraine mechanism was 
Wolff’s vascular theory. The idea was 
that vasoconstriction causes migraine 
aura and the following vasodilatation 
would cause throbbing headache. After 
breakthroughs in genetics, imaging and 
functional studies in migraine, the em-
phasis shifted for several years to neuro-
nal mechanisms and the vascular theory 
was almost completely rejected. Recent-
ly direction has turned again to the vas-
cular system, but the neuronal theory is 
as well accepted as before and thus mi-
graine should perhaps be considered a 
neurovascular or vasculoneuronal dis-
ease. The idea of this study is to shed 
light on migraine mechanisms from both 
of these directions by evaluating the as-
sociations of migraine to both neuronal 
and vascular phenomena.
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Table 1. International classification of migraine (ICD-10 code G43)
  ICD-10 CODE  DIAGNOSIS
1.1   G43.0   Migraine without aura
1.2   G43.1   Migraine with aura
1.2.1  G43.10   Typical aura with migraine headache
1.2.2  G43.10   Typical aura with non-migraine headache
1.2.3  G43.104   Typical aura without headache
1.2.4	 	 G43.105	 	 	 Familial	hemiplegic	migraine	(FHM)
1.2.5  G43.105   Sporadic hemiplegic migraine
1.2.6  G43.103   Basilar-type migraine
1.3   G43.82   Childhood periodic syndromes that are 
     commonly precursors of migraine
1.3.1  G43.82   Cyclical vomiting
1.3.2  G43.820   Abdominal migraine
1.3.3  G43.821   Benign paroxysmal vertigo of childhood
1.4   G43.81   Retinal migraine
1.5   G43.3   Complications of migraine
1.5.1  G43.3   Chronic migraine
1.5.2  G43.2   Status migrainosus
1.5.3  G43.3   Persistent aura without infarction
1.5.4  G43.3   Migrainous infarction
1.5.5  G43.3 +    Migraine-triggered seizure
  G40.x or G41.x  
1.6   G43.83   Probable migraine
1.6.1  G43.83   Probable migraine without aura
1.6.2  G43.83   Probable migraine with aura
1.6.5   G43.83    Probable chronic migraine 
REVIEW OF THE LITERATURE
1 Classification and clinical features of migraine
1.1 Migraine with and without aura
Migraine is in its best fascinating, but 
in its worst severely disabling disor-
der. It is highly prevalent globally. Mi-
graine attacks typically includes sev-
eral phases: i) premonitory symptoms, 
ii) aura, iii) headache, and iv) postdro-
mal symptoms. The common forms of 
migraine are migraine with aura (MA) 
and migraine without aura (MO). The 
most important differentiating feature 
between the two is a lack of the aura 
phase in subjects with MO, however, 
often the same individuals suffer from 
both kinds of attacks. The introduction 
of the International Criteria for Head-
ache Disorders (ICHD) by the Interna-
tional Headache Society (IHS) diag-
nostic criteria in 1988 (1) (Table 1) was 
an important step for the reliability 
and reproducibility of clinical migraine 
studies and the criteria was updated 16 
years later (ICHD-II, 2004) (2). 
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Migraine aura consists of reversible 
and gradually developing neurological 
symptoms lasting at least several min-
utes and less than an hour. They in-
clude visual, sensory, and/or language 
disturbances (table 3.). The most com-
mon symptom is scintillating scotoma. 
Subjects with MA might experience 
several kinds of attacks: aura without 
headache, aura with typical migraine 
headache, aura with headache not 
fulfilling the IHS criteria of migraine 
headache as well as MO attacks. Typ-
ically subjects with MA consider the 
aura phase more disturbing than the 
headache phase of the migraine attack. 
According to the IHS criteria, migraine 
attacks last 4-72 hours and they typi-
cally include the following clinical fea-
tures: a pulsating nature and an unilat-
eral location of headache, moderate or 
severe intensity of pain, aggravation by 
physical activity, nausea and/or vomit-
ing, and sensitiveness of senses (table 
2.). Typical triggering factors for mi-
graine attacks include stress, menstru-
ation, certain foods, sensory stimuli, 
irregular eating, lack of sleep and over-
sleeping. Premonitory symptoms may 
precede  actual aura and/or headache 
phase of the migraine attack by sever-
al hours and even days. Premonitory 
symptoms typically include a various 
combinations of fatigue, sensitiveness 
of senses, yawning, nausea, craving for 
foods and pallor (figure 1).
Table 2. Diagnostic criteria of migraine without aura according to International Criteria 
for Headache Disorders (ICHD-II) society diagnostic criteria of migraine without aura 
published by the International Headache Society.
    
A.	At	least	5	attacks1	fulfilling	criteria	B–D
B.	Headache	attacks	lasting	4–72	hours	(untreated	or	unsuccessfully	treated)
C. Headache has at least two of the following characteristics:
     1. Unilateral location
     2. Pulsating quality
     3. Moderate or severe pain intensity
					4.	Aggravation	by	or	causing	avoidance	of	routine	physical	activity	(eg,	walking	or	climbing	
stairs)
D. During headache at least one of the following: 
     1. Nausea and/or vomiting
     2. Photophobia and phonophobia
E. Not attributed to another disorder
13
PRODROMAL SYMPTOMS
Yawning, craving for food,
tiderness, irritability, etc.
NEUROLOGICAL AURA SYMPTOMS
Visual, sensory, speech disturbance,
hemisensory, hemiparetic, vertigo
VASCULAR HEADACHE
Moderate or severe, 
unilateral, pulsating, 
made worse by physical 
activity, associated with 
nausea, vomiting, 
sensitivity to light and 
sound
POSTDROMAL SYMPTOMS
“Hangover”, tiredness,
lethargy, burst of energy
Figure 1. Features of migraine attack in different phases.
Table 3. Diagnostic criteria of migraine with aura according to International Criteria 
for Headache Disorders (ICHD-II) published by the International Headache Society.
    
A.	At	least	2	attacks	fulfilling	criteria	B–D
B. Aura consisting of at least one of the following, but no motor weakness:
     1. Fully reversible visual symptoms including positive features  
									(eg,	flickering	lights,	spots	or	lines)	and/or	negative	features	(ie,	loss	of	vision)
					2.	Fully	reversible	sensory	symptoms	including	positive	features	(ie,	pins	and	needles)	
									and/or	negative	features	(ie,	numbness)
     3. Fully reversible dysphasic speech disturbance
C. At least two of the following:
     1. Homonymous visual symptoms and/or unilateral sensory symptoms
					2.	At	least	one	aura	symptom	develops	gradually	over	≥5	minutes	
									and/or	different	aura	symptoms	occur	in	succession	over	≥5	minutes
					3.	Each	symptom	lasts	≥5	and	≤60	minutes
D.	Headache	fulfilling	criteria	B–D	for	1.1	Migraine	without	aura	begins	during	the	aura	
     or follows aura within 60 minutes
E. Not attributed to another disorder
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 A separate rare migraine sub-
type is sporadic hemiplegic migraine 
(SHM), which is similar to FHM but 
there is no family history of analogous 
attacks (4). A large Danish epidemio-
logical survey found that the preva-
lence of hemiplegic migraine (HM) in 
Denmark is 0.01%. The familial and 
sporadic forms were equally frequent 
(5). Other than motor symptoms 90 
% of HM patients report visual, 80 % 
dysphasic and 70 % basilar symptoms 
as a part of their migraine aura (6). 
Additionally encephalopathy, coma, 
confusion, seizures, prolonged auras, 
cerebellar symptoms and mental retar-
dation are also a part of the reported 
spectrum of HM phenotypes (7). 
 Mutations in three ion trans-
porter genes, CACNA1A, ATP1A2 and 
SCNA1A genes, cause FHM type 1, 2 
and 3 respectively (8-10). The same 
genes, and especially ATP1A2, have 
also been indicated in SHM (11). Be-
cause of the wide spectrum of clinical 
manifestations and the lack of genetic 
similarities, it has been suggested that 
FHM should not be considered as a 
subtype of MA. It should  rather be con-
sidered as a one of the syndromic mi-
graines (12) even though family mem-
bers of FHM patients seem to have an 
increased risk of MA, which suggests a 
shared genetic background (13). 
1.2 Familial and sporadic 
hemiplegic migraine
Familial hemiplegic migraine (FHM) 
is a rare, autosomal dominantly inher-
ited subtype of migraine with aura. In 
FHM at least some attacks are associ-
ated with one-sided motor weakness of 
varying severity (table 4.) (2, 3). 
Table 4. Diagnostic criteria of familial hemiplegic migraine according to International Cri-
teria for Headache Disorders (ICHD-II) published by the International Headache Society. 
A.	At	least	2	attacks	fulfilling	criteria	B	and	C
B. Aura consisting of fully reversible motor weakness and at least one of the following:
     1. Fully reversible visual symptoms including positive features 
									(eg,	flickering	lights,	spots	or	lines)	and/or	negative	features	(ie,	loss	of	vision)
					2.	Fully	reversible	sensory	symptoms	including	positive	features	(ie,	pins	and	needles)	
									and/or	negative	features	(ie,	numbness)
     3. Fully reversible dysphasic speech disturbance
C. At least two of the following:
     1. At least one aura symptom develops gradually over 5 minutes 
         and/or different aura symptoms occur in succession over 5 minutes
					2.	Each	aura	symptom	lasts	≥5	minutes	and	≤24	hours
					3.	Headache	fulfilling	criteria	B–D	for	1.1	Migraine	without	aura	begins	during	the	aura	
         or follows onset of aura within 60 minutes
D.	At	least	one	first-	or	second-degree	relative	has	had	attacks	fulfilling	these	criteria	A–E
E. Not attributed to another disorder
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3 Pathophysiology of migraine
The classical idea of migraine patho-
physiology was the vascular theory of 
migraine by H.G. Wolff in the 1940s. 
The original hypothesis was that vaso-
constriction first causes migraine aura, 
which is then followed by compensa-
tory vasodilatation inducing migraine 
headache. However, migraine attacks 
are more than just a combination of 
aura and headache. It is often preceded 
by premonitory symptoms such as fa-
tigue, phonophobia and yawning, and 
is followed by postdromal symptoms, 
which supports the role of a central 
2 Epidemiology of migraine
Migraine and other primary headaches 
such as tension type headache (TTH) 
are common diseases and headache 
is estimated to be the most prevalent 
neurological symptom (14). A lifetime 
prevalence globally has been reported 
to be 66% for headache and 46% for 
TTH (15). 
 There are no biological mark-
ers for migraine or other primary head-
aches. Therefore the IHS standardized 
diagnostic criteria by IHS from 1988 
was crucial for comparable studies 
in headache epidemiology. Incidence 
rates reported for migraine were 580-
601 per 100 000 person-years in wom-
en and 160-222 per 100 000 person-
years in men in two studies performed 
in Denmark and the  U.S. (16, 17). The 
incidence was highest in childhood and 
adolescence peaking earlier among 
boys (16). In a longitudinal population-
based study in Denmark, the reported 
annual incidence for migraine was 8.1 
per 1000 person years (18). 
 The first study of migraine 
prevalence using the IHCD was per-
formed in Denmark and showed that 
the one-year prevalence is 6% in men 
and 15% in women (19). Stewart et al. 
investigated the one-year prevalence 
in the U.S. performing a large scale 
study by mailing questionnaires to 15 
000 households (20). Of 20 468 par-
ticipants, 17.6% of women and 5.7% of 
men fulfilled the ICHD-II for migraine. 
Prevalence was highest in individu-
als ages from 35 to 45. Furthermore, 
households having the lowest incomes 
had an elevated risk of migraine. Since 
then, numerous studies have been pub-
lished from different countries with 
analogous results (21)       
   Most of the studies on mi-
graine epidemiology do not sepa-
rate the prevalence figures of MA and 
MO. A small study in Finland found 
that the one-year prevalence of MA is 
8% in women and 2% in men, but the 
study was performed before the ICHD 
was published (22). Analogous results 
were reported in larger Danish study 
in which 7% of women and 4% of men 
studied had MA (23). Further studies 
have concluded that the prevalence of 
MA is less than one-third of the total 
migraine  prevalence (21).  
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mechanism over merely disturbances 
in intracranial vessels. Furthermore, 
a report demonstrating that changes 
in blood flow and migraine symptoms 
are not associated suggests neuro-
nal or neurovascular pathologies over 
just a vascular pathology behind the 
migraine attacks (24). The headache 
phase of migraine attacks have actually 
been reported to be better associated 
to hypoperfusion than to hyperperfu-
sion in positron emission tomography 
(PET) studies (25).         
 The premonitory symptoms 
and episodic nature of migraine raised 
a suspicion of important roles of the hy-
pothalamus and brainstem in the acti-
vation of migraine symptoms, which 
have since been confirmed by a PET im-
aging study (26). Therefore, headache is 
probably a consequence of activation of 
the trigeminovascular system (TGVS).      
 Migraine aura is believed to be 
a consequence of cortical spreading de-
pression (CSD). CSD has been demon-
strated with animal models as early as 
1940s in the form of  a slowly propa-
gating (2 to 6 mm per minute) depo-
larization wave (27). A brief hyperemia 
is followed by oligemia and neuronal 
suppression. Even though the link be-
tween CSD and the headache phase of 
a migraine attack is poorly understood 
in humans, there are studies demon-
strating CSD-inducing activation of 
TGVS in rats (28).       
Figure 2. Illustration of  the relevant anatomical structures involved in migraine patho-
physiology. Copyright © [2002] Massachusetts Medical Society. All rights reserved. 
(Reprinted with a permission from New England Journal of Medicine) (29).
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4 Genetics of migraine
Familial clustering and twin studies 
suggest that genetic mechanisms are 
involved in migraine and especially in 
MA (30). Many studies conducted ear-
lier have, however, not applied the IHS 
criteria and make no distinction be-
tween MA and MO. A Danish popula-
tion-based study addressed the heredity 
of migraine using the ICHD-II criteria 
and found that familial risk is differ-
ent in MA and MO. Relatives of pro-
bands with MO had 1,9 times risk for 
MO, and relatives of probands with MA 
had an almost four times greater risk of 
MA but no increasing risk of MO, sug-
gesting that MA and MO have different 
etiologies (31). MO seems to be a con-
sequence of both genetic and environ-
mental factors, whereas MA seems to 
depend more on genetic factors. How-
ever, they should still both be consid-
ered multifactorial diseases. Interest-
ingly, also spouses of MO patients have 
a slightly elevated risk of MO. 
 Several population-based twin 
studies (32-36) have examined the con-
cordance of migraine in monozygotic 
twins. Mulder et al. studied the preva-
lence and heritability of migraine in 
29717 twin pairs from six countries that 
participated in the GenomEUtwin proj-
ect (32). The prevalence of migraine was 
highest, 32-34%, in Danish and Dutch 
women and lowest, 10-13%, in Finland. 
The heritability was 34-57%. Two stud-
ies on Danish twins diagnosed using 
the ICHD-II criteria reported higher 
pairwise concordance rates in monozy-
gotic than in dizygotic twin pairs, there-
by providing additional support for the 
idea that genetic factors are involved in 
both MA and MO (33, 35).   
Figure 3. Two ion-channel genes CACNA1A and SCN1A and one coding for an ATP 
exchanger, ATP1A2 have been found to underlie Familial Hemiplegic Migraine.
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 Samples of cases and controls 
and families have been used to identify 
susceptibility loci and genes involved 
in migraine etiology. Despite numer-
ous candidate gene association stud-
ies, the only variant associated with 
MA in several populations to date is a 
polymorphism in the MTHFR gene on 
chromosome 1p36 (37). A Finnish and 
a German study, however, have not 
confirmed the  association between mi-
graine and the MTHFR C677T variant 
(38, 39).  Three ion-transporter genes, 
on the other hand, have been associ-
ated with FHM, a rare mendelian sub-
type of MA characterized by hemipare-
sis as a part of aura (figure 3). Ophoff et 
al. were the first to discover that mis-
sense mutations in the CACNA1A gene, 
encoding the α subunit of a voltage-
gated Ca2+ channel (FHM type 1) (8), 
can cause FHM. Mutations in CACN-
A1A are also associated with episodic 
ataxia type 2 and spinocerebellar atax-
ia type 6. FHM type 2 is caused by mu-
tations in ATP1A2, which encodes the 
α2 subunit of Na+/K+ ATPase (9). The 
third FHM gene, SCN1A, encodes the 
pore-forming α1 subunit of the neuro-
nal voltage-gated sodium channel (10). 
These findings have lead to the idea 
that common types of migraine might 
be channelopathies. Even though some 
individuals with CACNA1A mutations 
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Figure 4. Susceptibility loci and genes identified for migraine. The dashed circles show 
the chromosomal locations of the three known FHM genes in the human genome. The 
solid black circles indicate the chromosomal loci that have shown significant evidence of 
linkage either to MA or MO in genome-wide scans.
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in FHM families have a phenotype 
comparable of MA or MO, most of the 
linkage studies have not indicated evi-
dence of the involvement of the FHM 
genes in common types of migraine 
(30). Furthermore, a previous Finnish 
study indicates that common variants 
in ion channel genes do not have a ma-
jor role in MA susceptibility (40).
 Besides FHM, these genes 
have also been associated with epilep-
tic seizures. Mutations in CACNA1A 
are known to cause epileptic seizures 
(8, 41), ATP1A2 (9) is associated to be-
nign familial infantile convulsions (42) 
and SCN1A (10) is associated with gen-
eralized epilepsy with febrile seizures 
plus and severe myoclonic epilepsy of 
infancy.               
  Genes predisposing to MA or 
MO have not yet been identified al-
though several loci have been indicat-
ed in the genome-wide linkage analy-
ses (figure 4). Evidence of significant 
linkage has been found between a lo-
cus on chromosome 4q24 in Finnish 
MA families (43). A region close to this 
locus, 4q21, has been linked to MO in 
Icelandic families (44). In addition to 
locus/loci on 4q, several other chromo-
somal loci, shown in Fig 4,  have shown 
significant evidence of linkage either to 
MA or MO (45-47). 
 The International Migraine 
Genetics Consortium has launched a 
genome-wide association study (GWA) 
spanning three European populations 
(Finnish, Dutch, and German) to study 
the role of common single nucleotide 
polymorphisms in migraine. The Finn-
ish sample consists of over 1000 MA 
cases and over 4000 non-migraneous 
controls.  
 The identification of genes as-
sociated with migraine is obviously 
challenging, as with other complex dis-
eases. The lack of replication of identi-
fied migraine loci may be due to phe-
notypic and genetic heterogeneity of 
migraine. Even the use of ICHD-II 
phenotypes, as in most of the molecu-
lar genetic studies of migraine, has not 
helped identify susceptibility genes in 
common forms of migraine. Alterna-
tive approaches have thus been sug-
gested to deconstruct the end diagno-
sis of migraine. In latent-class analysis 
(LCA), individuals are classified into 
empirically derived groups on the ba-
sis of patterns of ICHD-II symptom 
clustering observed in a large Austra-
lian twin sample. Using this approach, 
Nyholt et al. have found significant evi-
dence of linkage to chromosome 5q21. 
They have also provided evidence for 
other new loci and confirmed previ-
ously reported loci influencing com-
mon migraine (48, 49). 
 Another approach, trait com-
ponent analysis (TCA), applies clini-
cal information of individual traits in 
the ICHD-II symptom data in order 
to classify patients into groups. Using 
this method and reanalyzing 50 Finn-
ish MA families, Anttila et al. detected 
significant evidence of linkage between 
a locus on chromosome 17p13 and trait 
pulsation.  The previous study on these 
families had indicated nominal evi-
dence of linkage between MA end diag-
20
nosis and 17p13 (50). A recent study by 
Anttila et al. with three different strat-
egies (clinical end-diagnosis, TCA and 
LCA) detected significant evidence of 
linkage to chromosome 10q22-q23 and 
the finding was replicated in two sepa-
rate population samples from Finland 
and Australia (51). 
 The LCA and TCA methods 
have so far been used only in linkage 
studies of migraine families where they 
have successfully identified new loci 
and replicated known migraine sus-
ceptibility loci. Case-control studies of 
genetic variants are, on the other hand, 
more suitable for effect-size estima-
tion. In the near future GWA on com-
mon migraine may clarify the role of 
single gene variants to specific traits. 
5 Treatment of migraine
Treatment of migraine includes phar-
macological and non-pharmacolog-
ical treatments. The latter involves 
avoiding triggering factors and oth-
er life-style modifications as well as 
treatments such as acupuncture. Phar-
macological treatments include acute 
and preventive agents. Different acute 
medications and their recommend-
ed doses following current treatment 
guidelines are listed in table 5.  
5.1  Selective 5-HT1B/1D agonists 
(triptans)
Abortive pharmacological treatment of 
migraine can be divided into two main 
classes (52). The Ergot alkaloids (used 
since 1926) and triptans (used since 
1991) are considered to be migraine- 
specific treatments while the nonsteroi-
dal anti-inflammatory drugs (NSAIDs) 
and paracetamol are non-specific. 
 The first triptan introduced 
was sumatriptan (53) and six more 
have since become available: zolmi-
triptan (54), rizatriptan (55), eletrip-
tan (56), naratriptan (57), almotriptan 
(58) and frovatriptan (59) (table 5). 
Triptans are 5-HT1B/1D agonists and 
in Finland they are considered to be 
first-line treatment for severe migraine 
attacks due to their efficacy and tolera-
bility. They have multiple mechanisms 
of action, including vasoconstriction of 
dilated cerebral blood vessels, inhibi-
tion of the  release of vasoactive neu-
ropeptides by trigeminal nerves and 
inhibition of nociceptive neurotrans-
mission (60). They all have the same 
contraindications: ischemic heart dis-
ease, ischemic stroke, Prinzmetal`s an-
gina, uncontrolled hypertension, preg-
nancy, basilar migraine and hemiplegic 
migraine. They are considered safe and 
well tolerated when used correctly (61) 
and do not increase the risk of stroke, 
myocardial infarction, cardiovascular 
death, ischemic heart disease and mor-
tality (62).
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5.2 Nonsteroidal anti-inflammatory 
drugs
Nonsteroidal anti-inflammatory drugs 
(NSAIDs) are probably the most com-
monly used acute medications for mi-
graine. NSAIDs block cyclo-oxygenase 
and thereby inhibit the synthesis of pros-
taglandins from arachidonic acid. Con-
vincing evidence of efficacy has been 
reported in agents such as acetylsalicyl-
ic acid (63), diclofenac (64), ibuprofen 
(65), and naproxen (66) (table 5).  
 
5.3 Paracetamol
Paracetamol is a widely used over-the-
counter analgesic and antipyretic. It 
has been reported to be more effective 
than a placebo when combined with 
metoclopramide (67) or codeine (68), 
but not alone (69). It has been shown 
to have a similar efficacy as acetyl-
salicylic acid (70), but is less effective 
when compared to NSAID’s (71). 
5.4 Corticosteroids
The role of corticosteroids in the treat-
ment of migraine and other headaches 
has been controversial. Small trials have 
demonstrated promising results for IV 
dexamethasone in headache recurrence 
prevention (72, 73), but recently Fried-
man et al. demonstrated in a 205-patient 
randomized placebo-controlled trial that 
10 mg IV dexamethasone is not effec-
tive in acute migraine treatment (74). A 
recent meta-analysis suggests a modest, 
but significant, benefit when dexametha-
sone is added to standard antimigraine 
therapy (75). Another meta-analysis 
concluded that dexamethasone is not ef-
fective in pain alleviation, but it signifi-
cantly reduces headache recurrence (76). 
Prednisolone has been found ineffective 
on withdrawal headache in patients with 
medication overuse and chronic daily 
headache (77). Supplementing dexa-
methasone treatment with rizatriptan 
has been reported to be more effective in 
treating menstrual migraine than rizat-
riptan alone (78). The theoretical back-
ground for the use of corticosteroids in 
migraine is based on observations that 
suggest a relationship between neuro-
genic inflammation and migraine (79, 
80). Migraine has also been demonstrat-
ed to have comorbidity with inflamma-
tory diseases such as allergy (81).
    
 5.5 Antiemetic drugs
Nausea (with or without vomiting) is, 
besides pain, often one of the main 
symptoms in migraine attacks, and 
therefore, the idea of using antiemet-
ics in migraine treatment seems rea-
sonable. Another indication that they 
might be useful is the possible de-
layed absorption of per oral medica-
tion in migraine treatment due to gas-
tric stasis (82). Antiemetics have been 
thought to support gastric emptying, 
thereby enhancing the efficacy of other 
per oral antimigraine medications such 
as triptans and NSAIDs (83). 
22
Metoclopramide is a benzamide deriv-
ative which is a dopamine and 5-HT3 
antagonist. Intravenous metoclo-
pramide has been reported to be ef-
fective in a placebo-controlled study 
of migraine treatment (84) and in high 
doses it is comparable to subcutaneous 
sumatriptan treatment in an  emer-
gency department setting (85). Orally 
administered metoclopramide alone 
has not been proven to be superior to 
placebo (86) but it is beneficial as an 
adjunct therapy with both sumatriptan 
(87) and tolfenamic acid (86).         
 Another antiemetic drug pro-
chlorperazine has been reported to 
be effective when administered intra-
muscularly or rectally. It is superior or 
comparable to metoclopramide when 
administered intramuscularly (88) or 
intravenously (89). 
Severe or disabeling headache   Dosage (mg)
TRIPTANS 
almotriptan     12.5 p.o.
eletriptan		 	 	 	 	 40–80	p.o.
frovatriptan     2.5 p.o.
naratriptan	 	 	 	 	 2.5–5	p.o.
rizatriptan	 	 	 	 	 5–10	p.o.
sumatriptan	 	 	 	 	 50–100	p.o.,	20	i.n.,	25	p.r.,	6	s.c.
zolmitriptan	 	 	 	 	 2.5–5	p.o.,	5	i.n.
ERGOTAMINES 
ergotamine     ad 2 p.o./p.r., ad 6/daily
dihydroergotamine     1 i.m. tai 0.5 i.v.
Mild or moderate headache 
ANTI-INFLAMMATORY MEDICATIONS 
acetylicsalicylic acid    1 000 p.o.
paracetamol     1 000 p.o./p.r.
diclofenac	 	 	 	 	 50–75
ibuprofen		 	 	 	 	 800–1	200
ketoprofen	 	 	 	 	 100–200
naproxen		 	 	 	 	 500–1	100
tolfenamic acid     200
ANTIEMETICS	(in	combination	with	agents	above)	
metoclopramide	 	 	 	 	 10–20	p.o./p.r.
prochlorperazine	 	 	 	 	 10–25	p.o./p.r.
 
p.o.=per oral
i.n.=intranasal
s.c.=subcutaneously
p.r.=per rectally
Table 5. Acute medications of migraine. Modified from the Finnish current treatment 
guideline (90).
23
5.6 Treatment of hemiplegic 
migraine
Patients with basilar migraine or HM 
have been excluded from randomized 
controlled triptan trials. The rationale 
for this exclusion is the possibility that 
the triptans would aggravate cerebral 
vasoconstriction and enhance the risk 
of ischemic stroke. Therefore, there 
are no randomized controlled prospec-
tive studies evaluating the clinical use 
of triptans in HM. However Klapper et 
al. presented a case report of 13 patients 
with basilar migraine, FHM or migraine 
with prominent or prolonged aura who 
had received triptans with excellent re-
sults and without adverse events (91). 
There are anecdotal reports of treat-
ment of HM with agents such as ver-
pamil (92, 93) and azetazolamide (94) 
but neither prospective nor large stud-
ies have been performed. According to 
one theory, vasodilatating agents such 
as calcium channel blockers might work 
in the acute or preventive treatment of 
FHM, but a recent case report described 
a prolonged FHM attack after intrave-
nous nimodipine infusion, suggesting 
caution (95).   
5.7 Preventive treatment of migraine
The rationale of preventive medications 
in the treatment of migraine is to di-
minish the activity of migraine by sev-
eral months lasting daily medication. 
Traditionally, preventive medication 
should be considered if patient has sev-
eral (three or more) monthly attacks. 
The most commonly used treatments 
include antiepileptic medications, anti-
depressants and antihypertensive med-
ications. Different prophylactic agents 
and dosages recommended in current 
treatment guideline are listed in table 6. 
 Antiepileptic drugs have been 
used in the treatment of migraine 
since the 1950s based on empirical ev-
idence, but the efficacy and tolerabil-
ity of agents, such as phenytoin and 
phenobarbital, were unsatisfactory. An 
early placebo-controlled study of carba-
mazepine in migraine prophylaxis was 
promising, reporting that 84 % (38/45) 
of the active treatment group improved 
compared to 27 % (13/48) in the control 
group (96). The strongest evidence of 
efficacy has been reported for valproic 
acid (VPA) and topiramate (TPM), but 
lamotrigine (LTG) has also been used, 
especially in the prophylaxis of auras 
(97). A Cochrane review concluded that 
antiepileptic drugs considered as a class 
reduce migraine frequency by 1,3 at-
tacks per 28 days compared to placebo 
(98). 
Valproic acid
Valproic acid (VPA) is an antiepileptic 
drug with a multiple mechanisms of ac-
tion (99). Besides epilepsy and migraine 
it is commonly used in the treatment of 
bipolar disorder (100) and sometimes 
in the treatment of cluster headache 
(101). The precise mechanism in mi-
graine alleviation is unclear, but the en-
hancement of GABAergic neuro-trans-
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mission seems to be the most likely 
(102). VPA increases GABA levels in the 
central nervous system in several ways: 
by stimulating the GABA synthetic en-
zyme (glutamic acid decarboxylase) 
and by inhibiting the GABA degrada-
tive enzymes (GABA aminotransferase 
and succinate semialdehyde dehydro-
genase) (102).           
 The first randomized and pla-
cebo-controlled study of VPA in the 
treatment of migraine was a small 
cross-over study in 29 migraine pa-
tients (table 2). The patients were 
given either 400 mg of VPA or a pla-
cebo for eight weeks and then crossed 
over for an additional eight weeks. Pa-
tients suffered 4,4 migraine attacks per 
month in the active treatment period 
compared to 7,8 attacks per month in 
the placebo period (103). The effica-
cy of VPA has been reported in differ-
ent daily dosages (500-1500mg) (104-
106). So far, the largest study on this 
subject was performed by Freitag et al. 
in a study of 237 migraine patients who 
were randomized to receive 500-1000 
mg of extended release VPA daily (122 
patients) or a placebo (115 patients) for 
12 weeks. The main outcome was the 
reduction of migraine activity with the 
VPA group showing a greater reduction 
than the placebo group (p < 0.006). 
Importantly there were no significant 
differences in the incidence of ad-
verse events between the groups (107). 
Small studies on acute treatment of mi-
graine with intravenous VPA have been 
carried out, but the number of patients 
has been too limited to show convinc-
ing evidence of efficacy (108).  
Topimarate 
Topiramate (TPM) is a wide-spectrum 
antiepileptic drug with a multiple mech-
anisms of action. Potential migraine al-
leviation has been suspected resulting 
from its effects on voltage-gated sodium 
channels and the enhancement of the in-
hibitory GABA system.  
 Storey et al. reported the poten-
tial efficacy of TPM in migraine prophy-
laxis in a small randomized controlled 
study (109). The result has been con-
firmed in larger studies with several dif-
ferent daily doses tested (50mg, 100mg 
and 200mg) (110, 111) and efficacy has 
been reported to continue for up to 14 
months (112).  Diener et al. reported that 
while the number of monthly migraine 
days increases after cessation of the TPM 
treatment, they do not return to pre-
treatment levels, suggesting sustained 
benefit even after discontinuing the 
treatment (113). Furthermore, TPM has 
been reported to be effective in the treat-
ment of chronic migraine. In an Italian 
study, the average number of days with 
headache per month was reduced from 
20,9 to 8,1 in subjects with a daily dos-
age of 50mg TPM (114) and results were 
confirmed by Silberstein et al. with a dai-
ly dose of 100mg TPM (115). The effica-
cy of TPM has been reported to be com-
parable to both propranolol in migraine 
prophylaxis (116) and VPA in the treat-
ment of chronic migraine (117).    
Gabapentin
Gabapentin (GPT) is an antiepilep-
tic drug that modulates Ca2+ chan-
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nels and increases GABAergic activa-
tion in the brain. Besides epilepsy GPT 
is commonly used in the treatment of 
neuropathic pain. After promising re-
sults in a small study of GPT in pro-
phylactic treatment of migraine (118), 
Mathew et al. performed a randomized 
double-blind study in 143 migraine pa-
tients (119). The frequency of migraine 
decreased from 4,2 monthly attacks to 
2,7 in patients receiving 2400 mg GPT 
daily and the difference was significant 
compared to patients receiving placebo 
in whom frequency decreased from 4,1 
monthly attacks to 3,5.     
Lamotrigine
Lamotrigine (LTG) is an antiepileptic 
drug that blocks voltage-sensitive sodi-
um channels, which in turn inhibits the 
neuronal release of glutamate. Besides 
in partial and generalized epilepsy treat-
ment, it has been used in treating bipo-
lar disorder and neuropathic pain (100). 
Steiner et al. conducted a randomized 
trial with 77 patients having active mi-
graine who received either 200 mg of 
LTG daily or a placebo for three months. 
Monthly attack frequency decreased by 
0,4 (3,6-3,2) in LTG treatment group 
and by 1,4 (4,4-3,0) in the placebo  group. 
Therefore, the study failed to prove the 
efficacy of LTG in the prophylactic treat-
ment of migraine (120). 
 Glutamate is a neuroexcitato-
ry amino acid and has been considered 
to play an essential role in the devel-
opment of CSD, a biological phenome-
non most likely causing migraine aura. 
Therefore, in the wake of the Steiner 
et al. study, it was believed LTG might 
only be useful in treating MA or aura 
alone. A small open study of 15 MA pa-
tients was set up to evaluate the efficacy 
of LTG in the prophylaxis of migraine 
aura. The reduction of aura symptoms 
was significant, from 1,3 per month to 
0,1 per month over the four-month 
treatment period, as well as the short-
ening of aura from 23 minutes to 4 min-
utes (121). Similar results were reported 
also in a small Italian open study of 24 
MA patients (122). Pascual et al. treat-
ed 47 MA patients with disturbing aura 
symptoms. A 50 % reduction of aura 
symptoms was considered positive re-
sponse and it was observed in 68% of 
patients (123). A similar end point was 
used in an open study of 59 MA patients 
of which 75 % experienced a positive re-
sponse (124). The frequency of migraine 
attacks was reduced from 2,1 to 1,2 per 
month and the median LTG daily dos-
age was 167 mg. Furthermore, there is a 
report suggesting the efficacy of LTG in 
epilepsy related auras (125).                   
Beta-blockers
Beta-blockers were primarily introduced 
to treat angina pectoris, arrhythmias and 
hypertension but the first reports of anti-
migraine effects are from as early as the 
sixties (126). Several different agents, 
such as propranolol, atenolol, metopro-
lol, bisoprolol and timolol, have been re-
ported to be effective in migraine pro-
phylaxis. A meta-analysis by Holroyd et 
al. concluded that propranolol reduced 
migraine activity by 44% compared to 
a 14% reduction in the placebo group 
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prophylaxis (128, 129). Good tolerabil-
ity makes candesartan especially useful 
in clinical practice.  
Tricyclic antidepressants
Amitriptyline is a tricyclic antidepres-
sant that inhibits both noradrenaline 
and 5-HT uptake. It has been reported to 
be effective in several randomized place-
bo-controlled trials (130). Sedation is a 
common side-effect and limits the use-
fulness of the agent in migraine prophy-
laxis, especially in higher dosages.    
Table 6. Preventive treatments of migraine. Modified from the Finnish current treatment 
guideline (90).
TREATMENT   DOSAGE (mg/d)   EFFICACY
BETA BLOCKERS  
Propranolol   40-240    ++
Metoprolol	 	 	 47.5-190	 	 	 	 ++
Atenolol    50-150    ++
Bisoprolol   5-10    ++
TREATMENTS AFFECTING 
THE RENINE-ANGIOTENSIN 
SYSTEM   
Candesartan   8-32    +
Eprosartan   300-600    +
Lisinopril    5-20    +
CALCIUM-CHANNEL BLOCKERS  
Verapamil   160-230    +
Nifedipin    30-60    +/-
Nimodipin   30-120    +/-
Flunarizine   5-10    ++
TRICYCLIC ANTIDEPRESSANTS  
Amitriptyline   10-50    ++
Nortriptyline   10-50    +
ANTICONVULSANTS  
Valproate    500-1500    ++
Topiramate   50-200    ++
 
++=good evidence of efficacy
+=moderate evidence of efficacy
+/-=poor evidence of efficacy
(127). Beta-blockers are considered es-
pecially good alternatives in migraineu-
rs with hypertension or angina pectoris, 
whereas for subjects with asthma or psy-
chiatric problems beta-blockers should 
be used only with caution.      
Treatments affecting renine-angio-
tensin system
Both angiotensin-converting enzyme 
inhibitors (lisinopril) and angiotensin 
II receptor blockers (candesartan) have 
been shown to be effective in migraine 
27
6 Comorbidity of migraine
Medical disorders can share comor-
bidity several different ways; i) coinci-
dently, ii) one may predispose another, 
iii) two conditions may share common 
pathophysiological, molecular genetic 
or environmental background. 
6.1 Ischemic stroke
6.1.1 Epidemiology
Migraine is a typically benign disorder of 
young people and the prevalence is two 
to three times higher in women than in 
men. Ischemic stroke (IS) is more preva-
lent in men and it typically affects older 
people more than migraine. IS is also typ-
ically a more serious threat to the health 
of an individual compared to migraine. 
Nevertheless, the association between 
the two disorders has been known for a 
long time and is profoundly-studied with 
several cohort, case-control and longitu-
dinal studies and two meta-analysis pub-
lished (131-147). A meta-analysis by Et-
minan et al. concluded that subjects with 
both MA (RR 2.27, CI 95% 1.61-3.19) and 
MO (RR 1.83, CI 95% 1.06-3.15) have an 
increased risk of IS (146). 
 One of the first publications 
on this subject was a case-control study 
of 89 IS patients and 178 controls. The 
prevalence of migraine with aura (MA) 
was 13 % in IS patients and only 5 % in 
controls (RR 2,6, CI 95 % 1,1-6,6). There 
was no difference in the prevalence of 
migraine without aura (MO) between 
groups (table 7.) (131). A French case-
control study of a 212 IS patients and 212 
controls found significant association 
between IS and the prevalence of mi-
graine in women under 45 years of age 
(132). Therefore, subsequent case-con-
trol studies have focused on young wom-
en (133-140). 
 A study of 308 young (15-44 
years) IS patients and their age and gen-
der matched controls reported a signifi-
cantly elevated prevalence of MA in IS 
patients compared to the controls (OR 
14,8), but there was no difference in the 
prevalence of MO (133). Another study 
using 72 young women with IS and 173 
controls reported both MA (OR 6,2) and 
MO (3,0) as risk factors for IS. Further-
more, the risk of IS was substantially 
greater in women with migraine using 
oral contraceptives (OR 13,9) or those 
who were heavy smokers (OR 10,2) 
(134). However, a recent large-scale co-
hort study found no association between 
oral contraceptives and risk of IS (148). 
Carolei et al. studied the  prevalence of 
migraine in 308 women under 45 with IS 
and in 591 controls. Migraine was more 
prevalent in IS patients than in controls 
(OR 1,9, 95 % CI 1,1-3,1), but the odds ra-
tio was even higher in the subgroup of 
women under 35 (OR 3,7, 95 % CI 1,5-
9,0) (136), suggesting an increasing im-
portance of migraine as a stroke risk fac-
tor in younger age groups. The result of a 
Finnish study of 506 working age IS pa-
tients differed from other studies show-
ing that migraine was stroke risk factor 
for stroke in men only (137).            
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Table 7. Migraine as a risk factor for ischemic stroke
STUDY   NO. OF STROKE   NO. OF  RR (95% CI) COMMENT
    PATIENTS (YEARS)  CONTROLS  
Henrich	et	al.	1989	 	 89	(18-65	years)	 	 178	 	 1.8	(0.9-3.6)	 Only	MA	
	 	 	 	 	 	 	 	 	 	 significant	
	 	 	 	 	 	 	 	 	 	 2.6	(1.1-6.6)
Tzourio	et	al.	1993	 	 212	 	 	 212	 	 1.3	(0.8-2.3)	 significant	only		
          in young 
          women 
	 	 	 	 	 	 	 	 	 	 4.3	(1.2-16.3)
Marini	et	al.	1993	 	 308	(15-44	years)	 	 308	 	 1.9	(1.0-3.5)	 	
Tzourio	et	al.	1995	 	 72	(women	under	45)	 173	 	 3.5	(1.8-6.4)	 	
Lidegaard	et	al.	1995	 497	(women	under	45)	 1370	 	 2.8	(2.0-4.2)	 	
Carolei	et	al.	1996	 	 308	(women	under	45)	 591	 	 1.9	(1.1-3.1)
Haapaniemi	et	al.	1997	 506	(16-60	years)	 	 345	 	 2.1	(1-2.9)	 significant	only		
          in men
Chang	et	al.	1999	 	 291	(women	under	45)	 736	 	 3.5	(1.3-9.6)	
Donaghy	et	al.	2002	 86	(women	under	45)	 214	 	 2.9	(1.2-7.1)	
Schwaag	et	al.	2003	 160	(under	46)	 	 160	 	 2.1	(1.1-3.8)	
Figure 5. Cumulative incidence of cardiovascular events in women experiencing active 
migraine with or without aura and women without migraine (Jama, 296 (3) 283-91, 
2006. Copyright © (2006) American Medical Association. All rights reserved) (149).
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  Cohort studies report similar results, 
suggesting that migraine approximate-
ly doubles the risk of IS compared to 
subjects without migraine (143-145). 
Figure 5 shows the incidence of car-
diovascular events in women with MA, 
MO and without migraine in a large co-
hort study (149).
 Two large longitudinal studies 
found significant association to IS only 
among subjects with MA (141, 142). 
Five years after Etminan’s meta-anal-
ysis, a new meta-analysis by Schürks et 
al. (147) concluded that only MA was 
a significant risk factor for IS, not MO 
(table 8) (147). Young age, oral con-
traceptives and smoking further in-
creased the relative risk. Migraine was 
only a risk factor among women.
    
6.1.2 Imaging
A Dutch CAMERA study in 2004 made 
news headlines in the U.S. The study 
included 161 MA patients, 134 MO pa-
tients and 140 healthy controls, non of 
which had a history of ischemic stroke 
symptoms (150). All patients were ex-
amined by brain MRI and blinded neu-
roradiologists estimated the amount 
of silent ischemic lesions and white 
matter lesions. Patients with migraine 
seemed to have slightly more silent 
ischemic lesions (8.1%) than controls 
(5.0%), but the difference was not sig-
nificant. However, in the posterior cir-
culation area migraineurs had seven 
times higher risk for silent ischemic le-
sions than controls. The difference was 
even greater in patients with active mi-
graine (at least one migraine attack per 
month) and subjects with MA had an 
OR 15.8 for silent ischemic lesions in 
the posterior circulation (CI 95 % 1.8-
140) (150). A meta-analysis of seven 
case-control studies reported that pa-
tients with migraine have a four-fold 
risk for white matter lesions than con-
trols (151).  
Table 8. Migraine and risk of cardiovascular events. Modified from a meta-analysis by 
Schürks et al. (147).
MIGRAINE TYPE AND VASCULAR EVENT  RELATIVE RISK (95% CI)
migraine	and	ischemic	stroke		 	 	 1.73	(1.31-2.29)
			women		 	 	 	 	 2.08	(1.13-3.84)
			men	 	 	 	 	 	 1.37	(0.89-2.11)
			<45	years	 	 	 	 	 2.65	(1.41-4.97)
			current	oral	contraceptive	use	 	 	 7.02	(1.51-32.68)
			smoking	 	 	 	 	 9.03	(4.22-19.34)
			migraine	with	aura	 	 	 	 2.16	(1.53-3.03)
			migraine	without	aura	 	 	 	 1.23	(0.90-1.69)
migraine	and	hemorrhagic	stroke	 	 	 1.18	(0.87-1.60)
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6.1.3 Patent foramen ovale
The comorbidity of MA, stroke and 
patent foramen ovale (PFO) as well as 
the implications of the comorbidity for 
clinical management has been a topic 
of considerable controversy in recent 
years. The epidemiological association 
of these conditions is well-document-
ed (146, 152-155). Transcranial doppler 
and transesophageal echocardiography 
(TEE) studies have demonstrated sig-
nificantly increased prevalence of right-
to-left shunt (RLS) in patients with MA 
compared to the migraine-free control 
population (152, 153). Young patients 
with cryptogenic stroke have been re-
ported to have a higher prevalence of 
PFO than healthy controls (155, 156), 
while MA has been associated with in-
creased risk of ischemic stroke in sever-
al epidemiological studies (146).  
 It has been hypothesized that 
PFO might predispose to both MA and 
ischemic stroke through paradoxical 
microscopic emboli. Passage of chemi-
cal substances normally eliminated in 
the lungs has also been suggested to 
be a possible trigger of migraine. It has 
been reported that paradoxical emboli 
frequently end up in the posterior cir-
culation (157), and furthermore, that 
MA patients with massive RLS tend 
to report that Valsalva-provoking ac-
tivities trigger their MA attacks (158). 
Therefore, it is possible that visual au-
ras are triggered by emboli that have 
traveled across the PFO, found their 
way to occipital areas via posterior cir-
culation and caused cortical spreading 
depression (159). 
 Retrospective and open stud-
ies have reported promising results in 
decreasing migraine activity after clo-
sure of PFO (160). Therefore several 
prospective studies have been started. 
Results of the MIST-trial, the only ran-
domized controlled study published 
thus far, was negative. The study in-
cluded 147 patients with active mi-
graine who were randomized into two 
groups: one undergoing the closure of 
PFO and the other receiving a sham 
procedure. The primary outcome of 
interest was whether patients experi-
enced complete migraine remission, 
but there was no difference between 
the groups (3/74 in active treatment 
group and 3/73 in sham group) (161). 
Furthermore there were no difference 
among secondary outcomes either. 
However, recently Vigna et al. report-
ed a study of 82 patients with migraine, 
subclinical brain lesions and PFO. The 
study was not randomized, but the de-
cision over whether the PFO was closed 
was based on the patients’ preferences. 
Migraine disappeared in 34% of the 
operated patients and 7% of controls 
(162). Importantly a recent large scale 
and the first population based study 
found no difference in prevalence of 
PFO between migraineours and con-
trols (163).     
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6.1.4 Cervical artery dissection 
(CAD)
In general atherosclerosis and cardiac 
embolism are the most common etiol-
ogies of ischemic stroke, but in young 
adults cervical artery dissection (CAD) 
has been reported to be the sole most 
common cause, being responsible for 
up to 18 % of strokes (164). The patho-
physiology and risk factors for CAD 
are incompletely understood, but since 
factors as diverse as high homocysteine 
levels, connective tissue disease, infec-
tion, manipulation of the neck and mi-
graine are suggested to be CAD risk 
factors, it seems likely that CAD is a 
multifactorial disease (165).   
 Migraine has been demon-
strated to be linked to CAD in several 
studies. In an early case-control study, 
40 % of 50 CAD patients and 24 % of 
100 controls reported a history of mi-
graine (166). Tzourio et al. reported 
that 49 % of CAD patients and 21 % of 
control patients had a history of mi-
graine (167). When migraine was di-
vided into subgroups the difference 
was still significant among MO pa-
tients, but importantly not in MA sub-
group. Recently Pezzini et al. evaluated 
the prevalence of migraine in 72 CAD 
patients and in control groups of sim-
ilar size. The prevalence of migraine 
was over seven times higher in CAD 
patients than in healthy controls (OR 
7,4 CI 95 % 3,1-17,6), but again there 
was no difference in prevalence of MA 
between the groups (168).
 Certain pathophysiological-
ly relevant genes have suggested links 
with migraine, CAD and IS. A methy-
lenetetrahydrofolate reductase (MTH-
FR) polymorphism has been associat-
ed to MA (169), but conflicting results 
have also been reported (38, 39). Pez-
zini et al. linked both migraine and the 
C667T MTHFR genotype to CAD sug-
gesting factors linking migraine and 
ischemic stroke (170). Furthermore, 
a large study reported that the same 
genotype in women with active MA in-
creases risk for ischemic stroke more 
than fourfold (171).      
6.1.5 Migrainous infarction (MI)
MI, according to the criteria of the 
ICHD-II is a rare condition (2) and the 
available clinical data are inadequate. 
Neurological deficit in a complicated 
migraine attack leading to MI should 
be similar to the aura in previous MA 
attacks and neuroradiological imaging 
should demonstrate an ischemic lesion 
in the corresponding region. In a study 
examining 2000 consecutive stroke 
patients during a 10-year period, only 
nine patients had MI according to the 
ICHD-II criteria for MI (172). Yet, they 
accounted for 14% of ischemic strokes 
in a subgroup of people younger than 
45 years of age. In earlier studies, the 
incidence of MI has been estimated to 
be 0.8-3.36/100000/year (173) (174), 
but these studies have important meth-
odological limitations as they were per-
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formed before the ICHD-II criteria for 
MI and the exclusion of other etiologi-
cal mechanisms has been insufficient. 
 MI appears to be more preva-
lent in women than in men (172, 175, 
176). The most common location of the 
ischemia has been reported to be in 
the occipital lobe (175).  However, the 
number of MI patients in some of these 
studies has been very low.
 The pathophysiology of MI is 
still unknown. A potential mechanism 
is ischemia induced by cortical spread-
ing depression, but other mechanisms, 
such as vessel wall alterations due to 
repeated arterial vasoconstrictions or 
hypercoagulability have been suggest-
ed (177).
6.1.6 MELAS and CADASIL
Mitochondrial encephalopathy, lactic 
acidosis, and strokelike episodes (ME-
LAS) is a syndrome with neurological 
manifestations caused by mutations in 
the mitochondrial genome. Up to 77% 
of MELAS patients have reported a 
history of migraine or other headache 
(178). Mitochondrial dysfunction has 
been suggested to be part of migraine 
mechanisms (179) and increased 
amounts of fats and accumulations of 
subsarcolemmal or interfibrillar mito-
chondria in muscle biopsies have been 
reported in patients with migraine-re-
lated stroke (180). However, MO has 
not been associated with mitochondri-
al mutations (181).  
     Cerebral autosomal dominant 
arteriopathy with subcortical infarcts 
and leucoencephalopathy (CADASIL) 
is the most common heritable cause of 
IS and vascular dementia. CADASIL is 
caused by mutations in the NOTCH3 
gene in chromosome 19q12 (182). Up 
to 20-40% of CADASIL patients have 
MA and typically migraine is the first 
symptom of the disease beginning at 
the age of 30 (183). 
6.2 Heart diseases
The reports of association between 
migraine and coronary heart disease 
(CHD) are conflicting, likely due to the 
several confounding factors between 
the two disorders. Preventive migraine 
treatments, such as beta-blockers and 
AT-II blockers, might decrease the 
prevalence of CHD in migraineurs as 
well as the use of aspirin in the acute 
treatment. Furthermore, CHD medi-
cations might alleviate migraine activ-
ity. On the other hand vasoconstricting 
agents, such as triptans, in acute treat-
ment have been suspected to increase 
the possibility of ischemia, but this 
seems unlikely (62).
     Kurth et al. evaluated the as-
sociation of migraine and cardiovascu-
lar events in women and reported that 
women with active MA have approxi-
mately a twofold risk for both ischemic 
stroke and myocardial infarction (184). 
The authors also analyzed the impact 
of the overall cardiovascular risk pro-
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file using the Framingham risk score. 
Interestingly in those women whose 
risk score was lowest the association 
of MA and ischemic stroke was high-
est (OR 3,88), whereas in those women 
whose risk score was highest the asso-
ciation of MA and myocardial infarc-
tion was highest (OR 3,34). Previously 
it has been reported that MA is associ-
ated with elevated risk of myocardial in-
farction (OR 2,1) in women and that MA 
is responsible for up to 18 major cardio-
vascular events per 10 000 women per 
year (149).  Myocardial infarction is also 
associated to migraine in men (185). 
However, a meta-analysis by Schürks 
et al. found no association between mi-
graine and myocardial infarction (147).  
  Mitral valve prolapse (MVP) 
is common valvular abnormality. Mi-
graineurs are reported to have over two 
times higher risk for mitral valve pro-
lapse (MVP) than controls (186). 
6.3 Blood pressure
Studies on the association between mi-
graine and blood pressure are contro-
versial and there are some important 
confounding factors complicating its 
study. Several drugs used in migraine 
prophylaxis are primarily antihyper-
tensive medications, such as beta-
blockers and angiotensin II receptor 
blockers (129). On the other hand, 
headache is one of the clinical features 
of hypertensive encephalopathy.  
 Previously, migraine was typ-
ically associated with hypertension 
(187). For the most part, recent stud-
ies show links between migraine and 
hypotension as well as decreasing mi-
graine activity with increasing blood 
pressure (188-190). A large popula-
tion-based prospective study from 
Norway reported association between 
increasing pulse pressure and systolic 
blood pressure with decreasing preva-
lence of headache (191). Another study 
found association between decreased 
systolic and elevated diastolic blood 
pressure with migraine (192). On the 
other hand, patients with MA have 
been reported to have higher blood 
pressure than controls (193).  
  
6.4 Epilepsy
Migraine and epilepsy share common 
clinical features, and therefore, the first 
publications about their association 
are over 100 years old. They are both 
paroxysmal disorders of the brain and 
patients are typically symptom-free be-
tween the attacks (194). Furthermore a 
loss of consciousness, the presence of 
auras, post-ictal drowsiness, aphasia 
and the possibility that attacks might be 
triggered by either visual or hormonal 
stimulus are all characteristics shared 
by both migraine and epilepsy as well 
as symptoms associated with gastroin-
testinal, psychological and autonomic 
nervous system conditions. Migraine 
attacks rarely trigger epileptic seizures, 
a phenomenon called migralepsy. Mi-
graine-like headache can be associated 
with epileptic seizures, especially post-
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ictally. Several antiepileptic treatments 
have been proven to work in migraine 
prophylaxis (see chapter 5.7).  
 On the population level prev-
alence of epilepsy has been estimated 
to be 0,5-1,0 %, but in migraine pa-
tients prevalence seems to be higher 
between 1,0 and up to 17,0 % (median 
5,9 %) (195). Ottman et al. interviewed 
1948 adult patients with epilepsy and 
1411 of their family members. A histo-
ry of migraine was reported by 24,4 % 
of epilepsy patients, by 23,0 % of fam-
ily members with epilepsy and by 11,9 
% of family members without epilepsy 
(196). The risk ratio for migraine was 
2,4 (95 %, CI 2,02-2,89) in epilepsy 
patients compared to controls without 
epilepsy. The risk of migraine was in-
creased in all subgroups of epilepsy pa-
tients, but surprisingly it was highest in 
the patients with epilepsy due to head 
trauma RR 4,1 (95 %, CI 2,92-5,70). 
Recently a Norwegian study found no 
association between migraine and ep-
ilepsy in a population-based study of 
1656 participants, but still there was a 
trend toward comorbidity, especially 
among subjects with MA (197).  
 An Italian study evaluated the 
prevalence of epileptic seizures in 137 
pediatric patients with different prima-
ry headache diagnoses and 10,2 % of 
these patients reported a history of sei-
zures (198). Seizures were significantly 
more prevalent in MA patients (30,4 
%) compared to patients with MO (4,8 
%) and tension type headache (5,1 %). 
A study by Leniger et al. evaluated clin-
ical characteristics of 61 patients with 
a comorbidity of migraine and epi-
lepsy compared to 280 patients with 
epilepsy alone and 248 patients with 
migraine alone. A significantly larger 
proportion of comorbid patients had 
MA (41,0 %) than from patients with 
migraine without epileptic comorbid-
ity (25,8 %) (199).  
 A population based case-con-
trol study, where migraine symptoms 
were evaluated, was carried out in 
Iceland with 145 cases with epileptic 
seizures and 188 controls. Migraine 
increased the risk for developing sei-
zures almost fourfold (OR 3,7; 95 % CI 
1,6-8,3), but importantly, association 
seemed to only be explained by MA pa-
tients in whom the OR was 8,2 (95 % 
CI, 2,3-28,9). In MO patients the OR 
was only 1,4 (95 % CI, 0,5-1,4) (200). 
Because MA commonly precedes sei-
zures, the authors interpreted that MA 
seems to have a causative role in epi-
lepsy. However, bidirectional comor-
bidity has been also suggested (201).           
 There are also some important 
differences between the diseases. The 
highest peak in incidence of migraine is 
in early adulthood, whereas in epilepsy 
peaks in both extreme ends of life. Fur-
thermore the clear female preponder-
ance in migraine prevalence is not evi-
dent among subjects with epilepsy.   
  Both migraine and epilepsy are 
paroxysmal brain disorders. They are 
believed to be a consequence of neu-
ronal hyperexcitability. However, mi-
graine seems to cause cortical spread-
ing depression and epilepsy seems to 
cause hypersynchronous activity. Other 
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than rare forms of migraine and epilep-
sy, a few other episodic disorders such 
as long QT-syndrome and periodic pa-
ralysis are believed to be consequences 
of disturbances in ion transport mole-
cules, so called channelopathies.  
6.5 Other primary headaches
The prevalence of tension-type head-
ache seems to be similar between MA, 
MO and non-migraineur controls, but 
the severity and frequency of tension-
type headache is higher in subjects 
with migraine compared to controls 
(202, 203).
 
6.6 Psychiatric disorders
Already in the late forties Harold G. 
Wolff published his theory about the 
connection between psychiatric disor-
ders and migraine. He explained the 
association with a so called “migraine 
personality”. According to the theo-
ry, persons with migraine personal-
ity were delicate, shy, well-mannered, 
stubborn, inflexible, often had an un-
due attachment to their mothers in 
childhood and had generally been pre-
occupied with moralistic and ethical 
problems in adolescence, particularly 
with respect to sex. In adulthood, sub-
jects were unusually ambitious, unable 
to relax, conscientious, perfectionist, 
meticulous, fastidious, poor at delega-
tion, overanxious, tense at work and 
unable to cope with criticism. 
 The migraine personality the-
ory is no longer mainstream, but the 
connection between migraine and de-
pression has been shown in numerous 
cross-sectional and longitudinal stud-
ies. The first study to report the associ-
ation in an unselected epidemiological 
setting was a study by Merikangas et al. 
(204). In the study, 457 young subjects 
from Switzerland were interviewed 
and migraine was significantly associ-
ated to depression (OR 2.2, 95% CI 1.1-
4.8). Breslau et al. have reported in a 
longitudinal study that subjects with 
migraine have a three-fold higher risk 
becoming depressed and vice-versa, 
suggesting a bidirectional association 
and shared mechanism between these 
disorders (205, 206). However, con-
flicting results about the bidirection-
al nature of the association have also 
been reported (207). A similar bidi-
rectional association has not been ob-
served between depression and other 
severe headaches other than migraine, 
even though severe headache increases 
the risk of depression (206). The risk 
of depression seems to increase with 
increases in the frequency of migraine 
headache (208), but depression does 
not have an impact on the prognosis 
of migraine (206). It seems depression 
has a stronger link to MA than MO 
(209), especially in women (210).        
 The nature of the association 
of these conditions is still only specu-
lation. Chronic painful diseases and 
unpredictable painful and disabling 
attacks may naturally stir thoughts of 
helplessness, anger and frustration 
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that lead to depression and/or anxi-
ety. On the other hand, migraine and 
chronic headache may be though of as 
a somatic manifestation of depression. 
However, migraineurs seem to have a 
higher risk of depression and anxiety 
than subjects with other chronic pain 
disorders such as arthritis and back 
pain (211), suggesting biological and 
shared mecnism.    
 Migraineurs have been report-
ed to have almost four times higher risk 
for generalized anxiety disorder (GAD) 
than controls (211). GAD subjects with 
migraine have been reported to have a 
higher risk for social phobia (204) and 
panic disorder (212). Subjects with mi-
graine and anxiety have been reported 
to have an extremely high risk for de-
pression (OR 22.8, CI 95% 12.7-41.2) 
(213).  
 Bipolar disorder is also asso-
ciated to migraine. Migraineurs are 
reported to have higher risk for bipo-
lar disorder than controls (8.8% vs. 
3.3%) (204) and subjects with bipolar 
disorder are reported to have a higher 
prevalence of migraine than controls 
(24.8% vs. 10.3.%) (214)  
6.7 Immunological diseases
6.7.1 Multiple sclerosis
According to different studies, lifetime 
prevalence of headache in patients with 
multiple sclerosis (MS) varies between 
4 % and 58 % (215). Zorzon et al. re-
ported in a case-control study that mi-
graine is an independent risk factor for 
MS (OR 13,5, 95 % CI 1,5-116,6) (216). 
Another study showed a stronger asso-
ciation of migraine with relapsing-re-
mitting MS (50,9 %) than progressive 
MS (18,7 %) (215). However, in a re-
cent large-scale study there was no dif-
ference in the prevalence of migraine 
between patients with MS and healthy 
controls (217). Lifetime prevalence of 
migraine in MS patients has been esti-
mated to be 16 % (218).      
6.7.2 Allergy and asthma
Migraine patients are often aware of 
how specific foods may act as triggering 
factors for a migraine attack. The first 
reports associating migraine and aller-
gy are from the 1800s. In 1927 Vaughn 
found  ten migraine patients with food 
triggers and showed that 36,4 % (12/33) 
of his migraine patients have an aller-
gy triggering migraine attacks. In the 
1950s, Unger et al. concluded that mi-
graine is probably an allergic disease 
because of the excellent relief of mi-
graine symptoms by avoiding triggering 
nutritional factors (219). The most com-
mon foods reported to cause migraine 
symptoms are wheat, orange, eggs, tea, 
coffee, chocolate, milk, beef, corn, cane 
sugar and yeast (220).             
 Patients with allergic rhinitis 
are reported to have a higher prevalence 
of migraine than controls (81) and mi-
graineurs have been reported to have el-
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evated plasma IgE and histamine levels 
(221). Histamine levels are also elevat-
ed during migraine attacks compared 
to inter-ictal levels of the same individ-
uals (222). Nevertheless anti-allergic 
and anti-asthmatic medications, such 
as montelukast and antihistamine have 
not been shown to be effective in mi-
graine prophylaxis (223, 224).    
     Migraine is associated with el-
evated risk of asthma (225). Aamodt 
et al. reported in the large Norwegian 
Head-HUNT study that patients with 
asthma had a 1,5 times higher risk of 
migraine. Furthermore the study dem-
onstrated that the risk of asthma in-
creases with migraine frequency (226). 
6.8 Gastrointestinal disorders
Investigation of the association be-
tween migraine and gastrointestinal 
disorders has several limitations or 
problems. Sometimes, and especial-
ly in children it is difficult to interpret 
whether gastrointestinal symptoms are 
reflecting independent disorders or 
whether they are part of the migraine 
cascade. Of the pediatric population, 
4,1 % fulfill the criteria of abdominal 
migraine (227), and although much 
more rare, it also appears in the adult 
population (228). Symptoms or disor-
ders like gastric ulcer, may be side-ef-
fects of migraine medications, such as 
aspirin, rather than independent dis-
orders. 
 Kurth et al. evaluated the prev-
alence of abdominal symptoms in mi-
graineurs and observed that 80,9% 
of migraine patients had had upper 
abdominal pain during previous 12 
months compared to 37,5% of controls. 
Importantly, the difference was stron-
ger among non-aspirin users compared 
to aspirin users (229). Elevated preva-
lence of abdominal pain was also re-
ported among migraineurs compared 
to controls in a large Finnish study of 
school children (230). An Italian study 
suggests association of helicobacter py-
lori with migraine and even points out 
possible alleviation of headache symp-
toms after eradication of the bacteria 
(231). However, subsequent studies 
on the subject have been controversial 
(232-234). 
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AIMS OF THE STUDY
The aims of the study were: 
• To study the comorbidity of migraine 
and its subtypes with other diseases 
such as epilepsy, allergy, psychiatric 
disorders, ischemic stroke and cervical 
artery dissection. (Studies I, III)
• To identify loci predisposing to mi-
graine aura. (Study II)
• To compare clinical characteristics of 
migraine in both patients with dissec-
tion and healthy controls. Furthermore 
the aim was to analyze effect of dissec-
tion to the activity of migraine. 
(Study III)
• To evaluate the efficacy and tolerabil-
ity of triptans in the acute treatment of 
rare migraine with aura variants suf-
fering hemiplegic migraine. (Study IV)
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SUBJECTS 
The Finnish Migraine Gene Project 
(I, II and IV)
Patients of studies I, II and IV were ob-
tained from the Finnish Migraine Gene 
Project (FMGP) for which migraine fam-
ilies have been collected nation-wide 
since 1992. The patients were recruited 
from seven headache outpatient neurol-
ogy clinics nation-wide (Helsinki, Kemi, 
Turku, Jyväskylä, Mikkeli, Tampere, 
and Seinäjoki) (235). When a member 
of a family, the index case, was clinically 
diagnosed by a neurologist as suffering 
from migraine, the index case was asked 
to contact all other migraineurs in the 
family to ask if they would also be will-
ing to participate in the study. If at least 
three possible migraine sufferers were 
willing to participate from the family, 
a validated questionnaire, the Finn-
ish Migraine Specific Questionnaire for 
Family Studies (FMSQFS) was mailed 
to each of them as well as to their par-
ents and siblings (236). All participants 
gave their informed consent. The study 
was approved by the local ethics com-
mittee in Helsinki University Central 
Hospital. 
 The FMGP included, at the 
time of the present study, 7496 indi-
viduals (63.3% women) from 1618 fam-
ilies. Data was sufficient for diagnostic 
evaluation in 7225 subjects of which 
4967 (68.7%)  were migraineurs (table 
9). For each participant the fulfilment 
of the current migraine criteria of the 
International Headache Society was as-
sessed. 2496 participants had MA and 
4623 had MO according to the ICHD-II. 
Most migraineurs were women, 75.8 % 
in the MA and 73.8% in the MO groups.
  
Cervical artery dissection 
database (III)
Cervical artery dissection (CAD) is a 
common cause of ischemic stroke in 
young adults. The CAD database con-
sists of all 346 verified CAD patients 
(aged ≥15) without subarachnoidal hem-
orrhage treated at the Helsinki Univer-
sity Central Hospital from January 1994 
to December 2008. All participants gave 
their informed consent. The study was 
approved by the local ethics committee 
in Helsinki University Central Hospital. 
Table 9. Distribution of the different diagnoses in the Finnish Migraine Gene Project 
 
    ALL   WOMEN (%)
Migraine	 	 	 	 4967	 	 	 3640	(73.4%)
Migraine	with	aura	 	 	 2496	 	 	 1892	(75.8%)
Migraine	without	aura	 	 4623	 	 	 3414	(73.8%)
No	migraine	 	 	 2258	 	 	 958	(42.4%)
All	 	 	 	 7225	 	 	 4624	(64.0%)
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Patients
Study I
Study I includes 1000 consecutive partici-
pants from the FMGP that belong to 251 
families (Table 10). Comorbidities were 
evaluated in 678 family-members with 
migraine and in 322 family-members 
without migraine. Two subjects were ex-
cluded from the study because they did 
not report their medical conditions.
Study II
Families in study II were selected from 
the FMGP based on the high preva-
lence of visual aura symptoms and the 
fulfilment of the IHS criteria for typi-
cal MA. The study sample consisted of 
351 subjects (224 women and 127 men) 
from 36 families.
Study III
Of the 346 patients in the CAD data-
base, 313 were included in the study. 
Thirty-three patients were excluded, 
because information regarding mi-
graine was missing: seven had died; 
four had severe aphasia; five were at 
nursing homes; and 17 patients could 
not be reached or refused to partici-
pate in the study. Controls, frequency-
matched by 5-year age intervals and 
sex within the CAD-group, were re-
cruited randomly with the help of the 
Finnish Population Register Center 
from the population living in the catch-
ment area of our hospital.
Study IV
At the time of analysis, the FMGP in-
cluded 5351 subjects (61.9% women) of 
which 3389 (63.3%) were migraineu-
rs. The database included 198 subjects 
with hemiparesis as a part of their mi-
graine aura. All 76 subjects with hemi-
plegic migraine who had used triptans 
at least once in the treatment of mi-
graine were included in study IV.
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Table 10. Study populations and subjects in studies I-IV. 
STUDY STUDY POPULATION  CASES   CONTROLS
I	 1000	consecutive	participants		 676	family	members	 322	family	members
 in the FMGP    with migraine  without migraine 
II Members of 36 consecutive   185 subjects with  166 subjects without
 families with high prevalence of  ICHD-II aura   ICHD-II aura
 MA from the FMGP  
III 346 subjects from the CAD database 313 CAD patients   313 healthy controls
IV	 198	family	members	with	HM	from		 76	family	members	with	 Controls	not	used
 FMGP    HM and triptan use 
FMGP=Finnish Migraine Gene Project
MA=Migraine with aura
ICHD-II=International Classification for Headache Disorders, 2nd edition
CAD=Cervical Artery Dissection
CAD database=All CAD patients (aged ≥15) treated at Helsinki University Central Hospital from 
January 1994 to December 2008   
HM=Hemiplegic migraine
MA=Migraine with aura
MO=Migraine without aura
HM=Hemiplegic migraine 
Figure 6. Illustration of the distribution of migraine diagnoses in the Finnish Migraine 
Gene Project (FMGP).
FMGP
MO MA
HM
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 In study IV, subjects were se-
lected from the FMGP database. Those 
patients who reported hemiparesis as a
part of their migraine aura in FMSQFS 
(236) were systemically interviewed by 
a research-neurologist (V.A) to confirm 
the diagnosis HM. The subjects were 
asked precise questions concerning vi-
sual, sensory, motor, dysphasic and 
basilar-type aura symptoms, and their 
frequency, severity, location, gradual 
development, sequence, length and age 
at onset. All diagnoses were based on 
the ICHD-II (2) and the individuals who 
fulfilled the criteria for both FHM and 
SHM and those who had used triptans 
at least once as an abortive treatment of 
migraine were included in study. 
 The efficacy of the triptans 
and treatment-related adverse events 
were rated on a scale from 0 to 10 (no 
response or side effects 0, excellent re-
sponse or unbearable side effects 10). In 
addition, subjects reported how many 
occasions they had used triptans and 
during which phase of a migraine attack 
(i.e. aura or headache) the medication 
had been taken. 
Genotyping (II)
DNA from the patients’ blood samples 
was extracted using either the standard 
phenol-chloroform extraction proce-
dure or the Autopure LS automated 
purification instrument (Gentra Sys-
METHODS
Questionnaire (I-IV)
Clinical data from the study partici-
pants was collected using the validated 
questionnaire FMSQFS. The FMSQFS 
includes precise questions concerning 
characteristics of migraine, such as, 
activity, comorbidity, hereditability, 
triggering factors, aura symptoms and 
treatment of migraine (236). The FM-
SQFS divides subjects into the follow-
ing ICHD-II based diagnostic catego-
ries: migraine aura without headache 
(ie. migraine equivalents, EQV); MA; 
migraine attacks fulfilling the criteria 
of both migraine with and without aura 
(MA+MO); migraine with aura not ful-
filling all the current criteria (UNC); 
MO; headache other than migraine 
(HA); and no headache (NO). 
 The comorbidity of migraine 
was studied by evaluating the medical 
illnesses reported in the FMSQFS. Ta-
ble 11 presents the wording (translated 
into English) concerning these illness-
es in the questionnaire. Family-mem-
bers with migraine were compared to 
family-members without migraine. 
Differences between migraine sub-
groups were noted as well. All comor-
bidities reported by the patients were 
noted and the following were chosen 
for closer study: epilepsy, stroke, hy-
pertension, hypotension, allergy and 
psychiatric disorders. Definition of hy-
potension was a blood pressure lower 
than 115/70 mmHg.
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Table 11. Wording used in the FMSQFS concerning illnesses of participants
Previous illnesses: 
Do you have or have you had: 
			-	Stroke	(or	cerebral	infarction)	 	 	 	 	 	 (		)
			-	Intracerebral	haemorrhage	 	 	 	 	 	 (		)
   - Other cerebral circulatory disorder
					of	what	kind:.....................................……………	 	 	 	 (		)
			-	Epilepsy	 	 	 	 	 	 	 	 (		)
			-	Seizure	 	 	 	 	 	 	 	 (		)
			-	Fit	of	unconsciousness	 	 	 	 	 	 	 (		)
			-	Fever	convulsion	as	a	child	 	 	 	 	 	 (		)
			-	Hypertension	 	 	 	 	 	 	 	 (		)
			-	Myocardial	infarction	 	 	 	 	 	 	 (		)
			-	Symptomatic	heart	disease	 	 	 	 	 	 (		)
			-	Cardiac	insufficiency	 	 	 	 	 	 	 (		)
			-	Atrial	fibrillation	 	 	 	 	 	 	 	 (		)
			-	Other	cardiac	arrhythmia	 	 	 	 	 	 	 (		)
			-	Ménièr’s	disease	 	 	 	 	 	 	 (		)
   - Eye disease 
						which:................................................................	 	 	 	 (		)
   - Diabetes 
						which:	...............................................................	 	 	 	 (		)
   - Cancer
						which:................................................................	 	 	 	 (		)
   - Rheumatic condition 
						which:................................................................	 	 	 	 (		)
   - Allergy or atopy: 
					which	one:		........................................................	 	 	 	 (		)
			-	Mental	disorder	 	 	 	 	 	 	 	 (		)
	 Depression,	severe	depression	 	 	 	 	 (		)
	 Anxiety	disorder	that	needed	treatment		 	 	 	 (		)
	 Panic	disorder	 	 	 	 	 	 	 (		)
	 Insomnia		 	 	 	 	 	 	 (		)
	 Other,	which:................................………	 	 	 	 (		)
			-	High	cholesterol	level	 	 	 	 	 	 	 (		)
			-	High	triglyceride	level	 	 	 	 	 	 	 (		)
			-	Do	you	have	or	have	you	had	some	other	significant	illness:	 	 	 (		)
     which:................................................................. 
					None	of	the	above		 	 	 	 	 	 	 (		)
			-	Your	latest	blood	pressure	value	was					..........		/		.......			mmHg		(systolic	/	diastolic)	
			-	You	do	not	remember	but	you	were	told	it	was	or	has	been:	 	 	 (		)
						High					(			)															Low					(			)															Normal					(			)	 		
FMSQFS=Finnish Migraine Specific Questionnaire for Family Studies
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the present study. There were 233 pa-
tients who were re-interviewed to fill in 
missing data.
 Both CAD patients and healthy 
controls were semistructurally inter-
viewed by a research neurologist (V.A., 
T.M.M.) and lifetime prevalence of mi-
graine and its subtypes were evaluated 
in both study groups. Migraine was di-
agnosed based on the ICHD-II classi-
fication criteria (2). Data on migraine 
characteristics were collected using 
the FMSQFS (236). The evaluated fea-
tures were migraine severity (mean age 
at onset of migraine, vomiting, typical 
length of attack and total number of 
moderate or severe attacks) and pos-
sible vascular properties of migraine 
(Raynaud phenomenon, prodromal 
neck sensations and pulsating nature 
of headache). Characteristics of CAD 
were compared between migraineurs 
and non-migraineurs. Furthermore, 
use of oral contraceptives and smoking 
were evaluated in both groups. 
 To study the effect of CAD 
on migraine, the patients were asked 
whether the activity of migraine had 
changed after CAD using the follow-
ing scale: i) complete alleviation of 
migraine, ii) marked alleviation of 
migraine, iii) slight alleviation of mi-
graine, iv) no influence, v) slight in-
crease, and vi) marked increase in mi-
graine activity.
tems, Minneapolis, USA). Genotyping 
of the DNA-samples was based on the 
LMS-MD10 microsatellite marker set 
(Applied Biosystems, Foster City, CA, 
USA) of 378 markers, with an aver-
age marker distance of 10 cM and per-
formed using the ABI 3730 capillary 
sequencing instrument as described by 
Anttila et. al. (51). For fine-mapping, 
eleven additional markers on chromo-
some 9q21-q31 were selected using the 
location, heterozygosity and primer in-
formation provided by the UCSC data-
base (http://genome.ucsc.edu/). 
Cervical artery dissection data-
base (III)
Potential subjects for study III were 
identified using a search of the Helsin-
ki University Central Hospital’s data-
bases for diagnoses related to CAD and 
stroke.  The medical records of individ-
uals diagnosed were reviewed by stroke 
neurologists. Radiological images of 
patients in whom CAD was considered 
possible were re-analyzed by an expe-
rienced neuroradiologist. In uncertain 
cases, the patient was excluded. All pa-
tients included in the study displayed 
one or more of the typical diagnostic 
radiological characteristics. Patients 
presenting with subarachnoid hemor-
rhage (SAH) were treated in a neuro-
surgical unit and were not included in 
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Statistics 
The data were recorded and analysed 
using the Statview 5.0 software pack-
age (Abacus Concepts, Inc., Berkley, 
CA, USA, 1996). Parametric test (T-
test), Chi-square and Fisher’s Exact 
test were applied when appropriate. 
Non-continuous data was analyzed 
with the Mann-Whitney U test. 
 A two-tailed value of P≤0.05 
was considered statistically significant. 
Odds ratios (ORs) and 95% confidence 
intervals were calculated by Binominal 
Logistic Regression Models with CAD 
and control groups as outcome vari-
ables, controlling for age, sex, hyperten-
sion, current smoking, and diabetes.   
 Two-point parametric link-
age analysis was performed using the 
LINKAGE (237) and HOMOG (238) 
programs. Affected-sib-pair (ASP) 
analysis was performed to investigate 
the possibility of recessive inheritance. 
For regions showing evidence of link-
age in the parametric two-point analy-
sis, multipoint non-parametric analy-
sis was performed using the SimWalk 
program (239). In the analyses, an af-
fecteds-only strategy was applied, and 
thus, only individuals fulfilling the di-
agnostic criteria of aura were treat-
ed as affecteds and all other individu-
als were set to unknown. A Lod Score 
under locus heterogeneity (LodHet) 
of 3.3 was considered significant evi-
dence of linkage (240). LodHet thresh-
olds of 1.9 were used to identify sug-
gestive evidence of linkage. 
Table 12. Methods used in studies I-IV
STUDY   METHODS
I   FMSQFS
II   FMSQFS + genome-wide linkage analysis 
III   FMSQFS + semistructural interview 
IV   FMSQFS + semistructural interview
FMSQFS=Finnish Migraine Specific Questionnaire for Family Studies 
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The 1000 participants of this study 
belonged to 251 separate families. 
60.6% (606 individuals) were women 
and 39.4% men.  The mean ages were 
40.0 years among all participants, 40.8 
years in women, 38.8 years in men. 
678 participants had migraine, 70.5% 
of the migraineours were women (478 
individuals) and 29.5% (200 individ-
uals) men. Of the migraineurs 16 pa-
tients were diagnosed with EQV, 226 
RESULTS
7 Migraineurs have an elevated risk for hypotension, allergy 
and psychiatric disorders (I)
with MA+MO, 140 with MA, 144 with 
UNC and 152 with MO. The mean age 
of the migraine patients was 38.5 years 
(39.6 years for women and 36.0 years 
for men). The mean age of the family 
members not affected by migraine was 
43.1 years (45.4 years for women and 
41.6 for men). Two participants did not 
report their medical illnesses and 43 
did not report their blood pressure.
COMORBIDITY  FAMILY MEMBERS FAMILY MEMBERS 
STUDIED  WITHOUT MIGRAINE WITH MIGRAINE      
	 	 	 N=676	 	 	 N=322	
	 	 	 %	 	 	 %	 	 	 OR	(95%	CI)	 	
Epilepsy	 	 	 4,1	 	 	 2,9	 	 	 1.38	(0.64-2.97)
Women	 	 	 3,1	 	 	 3,4	 	 	 0.76	(0.27-2.15)
Men	 	 	 6,1	 	 	 2,4	 	 	 2.84	(0.89-9.04)	 	
Stroke	 	 	 2,5	 	 	 1,6	 	 	 1.74	(0.66-4.60)
Women	 	 	 2,5	 	 	 2,2	 	 	 1.36	(0.37-5.10)
Men	 	 	 2,5	 	 	 1,3	 	 	 2.39	(0.48-11.73)
Hypertension	 	 11,8	 	 	 11,6	 	 	 1.11	(0.71-1.73)
Women	 	 	 11,5	 	 	 11,3	 	 	 1.25	(0.65-2.39)
Men	 	 	 12,1	 	 	 11,5	 	 	 1.12	(0.57-2.18)
Hypotension	 	 26,0	 	 	 20,7	 	 	 1.43	(1.02-2.01)
Women	 	 	 32,1	 	 	 30,8	 	 	 1.32	(0.83-2.09)
Men	 	 	 10,7	 	 	 16,3	 	 	 0.64	(0.32-1.14)
Allergy	 	 	 34,0	 	 	 22,0	 	 	 1.83	(1.34-2.51)
Women	 	 	 37,4	 	 	 22,0	 	 	 2.01	(1.26-3.19)
Men	 	 	 25,4	 	 	 22,2	 	 	 1.18	(0.73-1.92)
Psychiatric	disorder	 11,1	 	 	 2,9	 	 	 4.09	(2.11-7.92)
Women	 	 	 12,9	 	 	 5,6	 	 	 2.82	(1.28-6.19)
Men	 	 	 5,1	 	 	 1,3	 	 	 3.90	(1.03-14.67)
CI = Confidence Interval
OR = Odds Ratio
Table 13. Comorbidities in family members with migraine compared to family members 
without migraine
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 Distribution of comorbidities 
is shown in Table 13 between partici-
pants with and without migraine. Mi-
graine patients statistically signifi-
cantly reported more hypotension (OR 
1.43; CI 95% 1.02-2.01), allergy (OR 
1.83; CI 95% 1.34-2.51) and psychiatric 
disorders (OR 4.09; CI 95% 2.11-7.92) 
compared with their family members 
without migraine. Differences regard-
ing epilepsy, stroke and hypertension 
were not statistically significant. 
 Table 14 presents reported co-
morbidities in the different diagnos-
tic categories of the study. The MA, 
MA+MO and UNC groups reported 
significantly more allergy and psychi-
atric disorders compared to the NO 
category. The corresponding OR’s were 
as follows: MA 1.68 (CI 95% 1.01-2.79) 
for allergy and 3.46 (CI 95% 1.17-10.21) 
for psychiatric disorders; MA+MO 1.86 
(CI 95% 1.17-2.97) for allergy and 5.91 
(CI 95% 2.16-16.20) for psychiatric 
disorders; and UNC 1.68 (CI 95% 1.02-
2.78) for allergy and 5.21 (CI 95% 1.80-
15.05) for psychiatric disorders.            
 
 Additionally, subgroup analy-
sis showed that women with MA+MO 
reported more hypotension (OR 2.12; 
CI 95% 1.065-4.23) than women in the 
NO group and men with MA+MO re-
ported more epilepsy (OR 6.76; CI 95% 
1.028-44.48) and stroke (OR 15.19; CI 
95% 1.15-200.88) than men in the NO 
group. Epilepsy was also more preva-
lent among men with UNC (OR 5.88; 
CI 95% 1.063-32.57) compared to men 
in the NO group. There were no sig-
nificant differences between MO and 
NO groups or between EQV and NO 
groups.   
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Table 14. Comorbidites in family members with different study diagnoses in the Finnish 
migraine families
COMORBIDITY EQV MA MA+MO UNC MO HA NO CATEGORIES 
STUDIED        SIGNIFICANTLY    
         DIFFERENT FROM NO  
  N=16 N=140 N=224 N=144 N=152 N=116 N=206  
	 	 (%)	 (%)	 (%)	 (%)	 (%)	 (%)	 (%)	 OR	(95%	CI)	 	 	
Epilepsy	 	 0,0	 5,0	 4,5	 4,2	 3,3	 4,3	 1,9	 none	 	 	
Women	(N=20)	 0,0	 6,4	 3,7	 1,0	 1,1	 5,2	 2,9	 none	
Men	(N=17)	 0,0	 2,2	 8,1	 11,1	 6,3	 3,4	 1,5	 MA+MO	6.76	(1.028-44.48)
	 	 	 	 	 	 	 	 	 UNC	5.88	(1.063-32.57)
Stroke	 	 2,2	 2,1	 3,6	 2,1	 0,7	 2,6	 1,5	 none	
Women	(N=15)	 11,1	 2,1	 3,2	 2,0	 1,1	 1,7	 2,9	 none	
Men	(N=7)	 0,0	 2,2	 5,4	 2,2	 0,0	 3,4	 0,7	 MA+MO	15.19	(1.15-200.88)
Hypertension	 12,5	 10,0	 11,6	 11,1	 9,9	 7,8	 18,0	 none	
Women	(N=72)	 11,1	 9,6	 11,2	 14,1	 7,9	 10,3	 20,0	 none	
Men	(N=47)	 14,3	 10,9	 13,5	 4,4	 12,7	 5,2	 16,9	 none	
Hypotension 12,5 22,8 32,3 26,8 23,0 25,2 16,0 none 
Women	(N=186)	 22,2	 30,4	 37,3	 33,0	 27,7	 31,6	 20,9	 MA+MO	2.12	(1.065-4.23)
Men	(N=47)	 0,0	 6,8	 7,9	 12,2	 16,1	 18,5	 13,4	 none	
Allergy	 	 18,8	 33,6	 39,7	 36,8	 28,3	 22,4	 20,9	 MA	1.68	(1.01-2.79)	
	 	 	 	 	 	 	 	 	 MA+MO	1.86	(1.17-2.97)
	 	 	 	 	 	 	 	 	 UNC	1.68	(1.02-2.78)	
Women	(N=212)	 11,1	 37,2	 41,2	 38,4	 36,0	 25,9	 20,0	 MA	2.48	(1.18-5.23)	
	 	 	 	 	 	 	 	 	 MA+MO	2.67	(1.35-5.28)
	 	 	 	 	 	 	 	 	 UNC	2.36	(1.13-4.95)	
Men	(N=92)	 28,6	 26,1	 32,4	 33,3	 17,5	 19,0	 21,3	 none	
Psychiatric	 6,3	 9,3	 14,7	 11,8	 5,9	 5,2	 2,4	 MA	3.46	(1.17-10.21)	
disorder	 	 		 	 	 	 	 	 	 MA+MO	5.91	(2.16-16.20)
	 	 	 	 	 	 	 	 	 UNC	5.21	(1.80-15.05)
Women	(N=71)	 0,0	 11,7	 17,6	 14,1	 5,6	 10,3	 2,9	 MA	5.37	(1.13-25.49)	
	 	 	 	 	 	 	 	 	 MA+MO	10.16	(2.30-44.82)
	 	 	 	 	 	 	 	 	 UNC	7.65	(1.64-35.76)
Men	(N=13)	 14,3	 4,3	 0,0	 6,7	 6,3	 0,0	 2,2	 none	
CI = Confidence Interval; OR = Odds Ratio; MA=migraine with aura; MO=migraine without aura; 
UNC=unclassified migraine; HA=headache; NO=no headache
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8 A visual migraine aura locus maps to 9q21-q22, 
a known occipitotemporal lobe epilepsy locus (II)
ing to the ICHD-II criteria. Among this 
group, 185 (52%) had aura fulfilling the 
ICHD-II criteria, 25 had non-ICHD-II 
aura and 35 had no aura at all while 
having ICHD-II headache (i.e. they 
had pure MO). Table 15 summarises 
the aura and headache characteristics 
of the study population. 
Table 15. Phenotypes of the genotyped individuals categorized by aura symptoms
MIGRAINE AURA  HEADACHE   N  % FEMALE
ICHD-II-aura   Migraine headache   160 d	 	 79.4
   Probable migraine headache c 13  46.2
   Non-migraine headache  8  25.0
   No headache    4 e  25.0
Total	(ICHD-II-aura)a	 	 	 	 	 185	 	 73.5
Unclassified	aura	 	 Migraine	headache		 	 25	 	 72.0
   Probable migraine headache c 5  60.0
   Non-migraine headache  3  100.0
   No headache    1  100.0
Total	(Unclassified	aura)b	 	 	 	 	 34	 	 73.5
No aura   Migraine headache   35 f  60.0
   Probable migraine headache c	 28	 	 42.9
   Non-migraine headache  12  58.3
	 	 	 No	headache		 	 	 48	 	 37.5
Total	(No	aura)	 	 	 	 	 	 123	 	 47.2
Missing	diagnosis	 	 Missing	diagnosis	 	 	 9	 	 55.6
a Total number of individuals having aura fulfilling ICHD-II criteria of migraine aura but the migraine 
headache does not necessarily fulfil the ICHD-II criteria   
b  Total number of individuals with unclassified aura refers to patients that are suffering from aural 
features that do not fulfil all ICHD-II criteria for migraine aura. The migraine headache also does 
not necessarily fulfil ICHD-II criteria 
c Probable migraine refers to patients with episodic headaches with some migraineous features 
that do not fulfil ICHD-II criteria for migraine without aura
d Number of individuals with the end diagnosis of migraine with aura
e Number of individuals having migraine aura without headache, i.e. equivalent migraine
f Number of individuals with the end diagnosis of migraine without aura
The study sample consisted of 36 fami-
lies and 351 (224 women and 127 men) 
individuals. The mean number of MA 
affected individuals per family was 5 
and the average family size was 15 indi-
viduals in three generations. The distri-
bution of migraine diagnoses is shown 
in Table 15. Of the 351 genotyped in-
dividuals, 245 had migraine accord-
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Table 16. Distribution of different aura symptoms in 185 subjects with ICHD-II aura
SCINTILLATING SCOTOMA      HOMONYMIC HEMIANOPIA      SPEECH DISTURBANCES      HEMIPARESIS
	 86%	 	 																										69%	 																													41%	 																					25%	
All subjects with ICHD-II-aura had vi-
sual aura (scintillating scotoma, hom-
onymic hemianopia or both) (table 
16.). A remarkably large proportion of 
subjects reported motor symptoms or 
speech disturbances beyond their visu-
al symptoms as a part of their aura, but 
only occasionally (table 16).
 The parametric two-point 
linkage analysis showed significant ev-
idence of linkage (LodHet=4.67) be-
tween migraine aura and a locus on 
9q31 (D9S1690 at 104.1 cM). Further 
evidence of linkage to four other mark-
ers surrounding D9S1690 was detect-
ed in the ASP analysis. The summa-
ry plots of both parametric two-point 
LodHet scores and non-parametric 
ASP values for chromosomes 1-22 and 
X are shown in figure 7. Non-paramet-
ric multi-point analysis indicated sig-
nificant evidence of linkage (p<0.01) 
between 9q22-q31 and migraine aura, 
supporting the evidence of a visual 
aura locus on 9q21-q31.
 The highest linkage signal 
was detected when all individuals with 
aura, including those having aura with-
out headache, were considered affect-
ed (table 17). Significant but reduced 
evidence of linkage (LodHet 4.31) was 
observed when subjects with both the 
headache and aura were analysed. 
When all the 220 individuals fulfilling 
the IHS criteria for migraine headache 
were considered as affecteds (includ-
ing the 160 individuals with the MA 
end-diagnosis), the linkage signal was 
inflated by 1.8 units (to suggestive evi-
dence of linkage, LodHet 2.91).
Table 17. Lod scores in different end-diagnoses
ANALYZED PHENOTYPES    LODHET   N
Subjects with ICHD-II-auraa	 	 	 4.7	 	 	 185
Subjects with MAb    4.3   160
Subjects with migraine headachec	 	 2.9	 	 	 220
a All subjects fulfilling ICHD-II criteria of migraine aura (with or without headache)
b All subjects fulfilling ICHD-II criteria of MA  
c All subjects fulfilling ICHD-II criteria of migraine headache (with or without aura)
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To increase the linkage information 
and to further narrow the susceptibil-
ity locus, eleven additional microsat-
ellite markers were genotyped in the 
linked region extending from 85 cM 
to 124 cM with a mean map distance 
of 2.7 cM.  When those markers were 
included with the original markers in 
the non-parametric multi-point link-
age analyses, the highest linkage sig-
nal modelling dominant inheritance 
was found at 94.7 cM (pdom=0.0003), 
approximately 10 cM proximal from 
the best marker (D9S1690) identified 
in the two-point linkage analysis. Sex-
specific, two-point parametric linkage 
analysis for chromosome 9 did not im-
prove the linkage signal.  
Figure 7. Results of the genome-wide linkage analyses for visual migraine aura. Plots of 
parametric (black bars) and non-parametric (grey bars) two-point linkage analysis for 
chromosomes 1-22 and X. The dotted horizontal line shows the significance threshold in 
HLOD.
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Figure 8. Family-specific haplotypes shared by all or almost all of the affecteds in the 22 
families that showed evidence of linkage in the 9q21–q31 region. Marker positions (cM) 
are based on the deCODE genetic map. The grey area, including the markers D9S253, 
D9S283 and D9S1796, indicates the extent of the shared region in 17 of the 22 families. 
This refined linkage region extends from 86 to 98 cM and covers 9.8 Mb. The last col-
umn, labeled “aura”, lists the proportion of affecteds with the shared haplotype, exclud-
ing married-in spouses. The bottom of the figure shows the genes in the region as pre-
sented by the UCSC database (March 2006 assembly).
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9 Migraine with aura is a risk factor for cervical artery dissection (III)
To further restrict the linked region 
and to identify the susceptibility gene, 
a haplotype analysis was performed 
(figure 8). The 22 families that had 
a family-based linkage score above 
0.3 (SimWalk dominant statistics 
pdom<0.5) at and around the highest 
linkage location were analyzed. These 
families contained 208 genotyped in-
dividuals of which 106 are considered 
affected with visual aura. In 17 out of 
these 22 families, affected individuals 
shared a family-specific haplotype be-
Table 18. Demographic and migraine related features of subjects with CAD and controls
   DISSECTIONS CONTROLS P VALUE
Mean	age	(y)	 	 46.1	 	 45.8	 	 0.79
Women	(%)	 	 105/313	(33.5)	 105/313	(33.5)	 1.0
Current	smoking	(%)	 115/313	(36.7)	 71/313	(22.7)		 <0.001
Hypertension	(%)	 	 129/313	(41.2)	 75/313	(24.0)	 <0.001
Diabetes	(%)	 	 12/313	(3.8)	 21/313	(6.7)	 	0.11
Oral	contraceptives		 38/105	(36.2)	 26/105	(24.8)	 0.072
(%	of	women)	
tween the markers D9S253-D9S1796 
from approximately 86 cM to 98 cM. 
The haplotype region was restricted 
on both sides due to recombinations in 
eight families. 
 In addition to chromosome 9, 
the ASP analysis found suggestive ev-
idence of linkage between migraine 
aura and 5q13 (ASP Lod 1.8 at 91 cM). 
Parametric analysis found nearly sug-
gestive evidence of linkage to 12p13 
(HLOD 1.8 at 15 cM).  
Of the 313 consecutive CAD patients 
(105 women and 208 men), 288 
(92.0%) had uniarterial and 25 (8.0%) 
had two-vessel CADs. The mean age at 
CAD onset was 46.1 years (range 15 to 
78, median 45) (table 18). The mean 
age of controls was 45.8 years (range 
21 to 74, median 45, P=0.79). Among 
CAD patients, male preponderance 
was observed (66.5%, P<0.001). Smok-
ing was more common among subjects 
with CAD than in controls (36.7% vs. 
22.7%, P<0.001). Hypertension was 
more prevalent among subjects with 
CAD than in controls (42.1% vs. 24.0, 
P<0.001). Current oral contraceptive 
use occurred in 36.2% of female CAD 
patients and in 24.8% of healthy fe-
male controls (P=0.072). There was 
difference in prevalence of diabetes be-
tween studied groups (3.8% vs. 6.7%). 
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Migraine and especially MA were more 
common among CAD patients than in 
controls (Table 19.). Accordingly, mi-
graine prevalence was 36% (114/313) 
for CAD patients and 23% (71/313) for 
controls (OR 2.15; 95% CI 1.48-3.14), 
while 23% (71/313) of CAD patients 
and 12% (39/313) of controls had MA 
(OR 2.41; 95% CI 1.53-3.80). Percent-
ages and adjusted ORs of reported mi-
graine history and MA in CAD patients 
and in controls presented separately for 
both genders were as follows: for wom-
en; migraine 54% (57/105) vs. 35% 
(37/105) (OR 2.30; 95% CI 1.28-4.13), 
MA 35% (37/105) vs. 18% (19/105) (OR 
2.79; 95% CI 1.40-5.59); for men; mi-
graine 27% (57/208) vs. 16% (34/208) 
(OR 2.02; 95% CI 1.23-3.31), MA 16% 
(34/208) vs. 10% (20/208) (OR 2.21; 
95% CI 1.19-4.11). There were no dif-
ferences in prevalence of MO between 
CAD patients and controls. 
   DISSECTIONS (%)        CONTROLS (%) ADJUSTED OR 95% CI
All    
Migraine	 	 	 114/313	(36)	 	 71/313	(23)	 2.15	 	 1.48-3.14
Migraine	with	aura	 	 71/313	(23)	 	 39/313	(12)	 2.41	 	 1.53-3.80
Migraine	without	aura	 43	(14)	 	 	 32/313	(10)	 1.64	 	 0.98-2.76
Women    
Migraine	 	 	 57/105	(54)	 	 37/105	(35)	 2.30	 	 1.28-4.13
Migraine	with	aura	 	 37/105	(35)	 	 19/105	(18)	 2.79	 	 1.40-5.59
Migraine	without	aura	 20/105	(19)	 	 18/105	(17)	 1.60	 	 0.74-3.49
Men    
Migraine	 	 	 57/208	(27)	 	 34/208	(16)	 2.02	 	 1.23-3.31
Migraine	with	aura	 	 34/208	(16)	 	 20/208	(10)	 2.21	 	 1.19-4.11
Migraine	without	aura	 23/208	(11)	 	 14/208	(7)	 1.75	 	 0.84-3.65
Table 19. Lifetime prevalence of migraine in patients with cervical artery dissection 
(n=313) and healthy controls (n=313). Odds Ratios are adjusted for age, sex, oral contra-
ceptives, hypertension, diabetes and current smoking.  
Table 20. Features of CAD in subjects with and without migraine
   MIGRAINE (%)  NON-MIGRAINE (%) P VALUE
Vertebrobasilar	dissection	 56/114	(49)	 	 92/199	(46)	 	 0.62
Bilateral	dissection	 	 9/114	(8)	 	 	 16/199	(8)	 	 0.94
Occlusion	 	 48/114	(42)	 	 87/199	(44)	 	 0.85
NIHSS at onset  3.3   4.4   0.30
Rankin at 3 months  1.1   1.3   018
Intracranial	dissection	 32/114	(28)	 	 59/199	(30)	 	 0.77
Ischemic	stroke	 	 77/114	(67)	 	 144/199	(72)	 	 0.37
NIHSS=National Institutes of Health Stroke Scale
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71% percent (223/313) of all CAD pa-
tients suffered from ischemic stroke. 
No difference in the incidence of brain 
infarct between migraineurs (67%) and 
non-migraineurs (72%) was apparent 
(table 20). Neither were the differenc-
es between migraineurs and non-mi-
graineurs when considering whether the 
affected arteries were bilateral (8% vs. 
8%), intracranial (28% vs. 30%), verte-
brobasilar (49% vs. 46%) or had occlu-
sion caused by a dissected artery (42% 
vs. 44%). Furthermore, the severity of 
neurological deficits at onset accord-
ing to the National Institutes of Health 
Stroke Scale (median 1.5 vs. 2.0; mean 
3.3 vs. 4.4, P=0.27) and the outcome at 
three months on the modified Rankin 
Scale (median 1.0 vs. 1.0; mean 1.1 vs. 
1.3, P=0.20) were similar between pa-
tients with and without migraine.
 Other variables lacking signifi-
cant correlation were severity and vas-
cular features of migraine between sub-
jects with CAD and controls (table 21). 
Mean age at onset of migraine was 18.4 
years in subjects with CAD and 19.2 
years in controls. The corresponding 
figures concerning the typical length of 
attacks were 13.9 hours vs.17.9 hours, 
the number of moderate or severe at-
tacks was 149.2 vs. 87.9 (P=0.19), 
the pulsating nature of headache was 
50.0% vs. 50.0%, and the prevalence of 
the Raynaud phenomenon was 15.4% 
vs. 14.5%. Subjects with CAD reported 
more prodromal neck sensations asso-
ciated to migraine (26.5%) than con-
trols (9.3%) (P=0.02) as well as more 
vomiting, 71.1% vs. 50.0% (P=0.044).    
Table 21. Migraine-related and vascular features in patients with cervical artery dissec-
tion and controls
     DISSECTION CONTROLS P VALUE
Age	at	onset	(y)	 	 	 	 18.4	 	 19.2	 	 0.64
Typical	length	of	attack	(h)	 	 	 13.9	 	 17.9	 	 0.41
Number	of	moderate	or	severe	attacks	 	 149.2	 	 87.9	 	 0.19
Vomiting	 	 	 	 	 71.1%		 	 50.0%		 	 0.044	
Raynaud	phenomenon	 	 	 15.4%	 	 14.5%	 	 0.90
Prodromal	neck	sensation	 	 	 26.5%	 	 9.3%	 	 0.021
Pulsating	pain	 	 	 	 50.0%	 	 50.0%	 	 1.0
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Information about the influence of dis-
section on the activity of migraine was 
obtained from 57 CAD patients (figure 
9), of whom 51% (29/57) reported de-
creased migraine activity immediately 
after CAD (complete remission in 13, 
significant decrease in 11, and slight de-
crease in 5). A minority of CAD patients 
reported a slight increase in migraine 
activity. The alleviation of migraine af-
ter CAD did not depend on whether the 
subjects suffered from stroke (50%; 
18/36) or not (52%; 11/21). The rest 
(44%; 25/57) of the patients did not re-
port any change in migraine activity af-
ter CAD, but in 48% (12 out of 25) of 
these patients, migraine was no longer 
active at the time of the dissection.
Figure 9. Distribution of the different reported effects of CAD in the activity of migraine.
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Table 22. Distribution of reported responses to triptans in 76 patients with hemiplegic 
migraine selected from the Finnish Migraine Gene Project (FMGP)
TREATMENT RESPONSE     %
Excellent a      63.5
Moderate b      21.6
Poor c	 	 	 	 	 	 	 14.9
a reported response from 8 to 10 on a scale from 0 to 10 
b	reported	response	from	3	to	7	on	a	scale	from	0	to	10
c reported response from 0 to 2 on a scale from 0 to 10  
The average reported adverse event se-
verity was 4.9 (SD +/-3.3) on a scale 
from 0 to 10.  The distribution of re-
ported adverse events are shown in ta-
ble 23. 
 The most reported side effects 
were chest pain, nausea and fatigue. 
One patient reported unconsciousness 
and hemiparesis, and another patient 
reported hemiparesis. These symp-
toms had also occurred earlier dur-
ing their attacks without triptan treat-
ment. No one reported ischemic stroke 
or myocardial infarction as an adverse 
event. The distribution of reported side 
effects is shown in table 24.
10 Treatment of hemiplegic migraine with triptans (IV)
In the FMGP database, 198 patients 
had hemiplegic migraine fulfilling the 
ICHD-II criteria and the 76 (38.4%) of 
them had used triptans at least once as 
an abortive treatment of migraine were 
included in the study. The mean age 
was 42.9 and 92.1% (70 individuals) 
were female. FHM was diagnosed in 
40 patients originating from 33 FHM 
families. 36 patients had SHM. The cri-
teria of basilar type migraine were ful-
filled by 37 patients (48.7 %). On aver-
age, the participants had used triptans 
on 257.2 occasions (SD +/-450.3). The 
average reported triptan response on a 
scale from 0 to10 was 6.9 (SD +/-3.1) 
and the distribution of reported re-
sponses are shown in table 22.
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Table 24. Distribution of the reported side-effects of triptans in hemiplegic migraine pa-
tients selected from the Finnish Migraine Gene Project (FMGP)
 
REPORTED SIDE-EFFECT     %
Chest	pain	 	 	 	 	 	 27.6
Nausea       26.3
Fatigue       22.4
Tachycardia	 	 	 	 	 	 9.2
Confusion      6.6
Worsening of pain      5.3
Worsening of aura      5.3
Uncosciousness      2.6
Hemiparesis      2.6
Table 23. Severity of the reported adverse events to triptans in 76 patients with hemiple-
gic migraine selected from the Finnish Migraine Gene Project (FMGP)
TREATMENT ADVERSE EVENTS    %
Severe a       28.4
Moderate b	 	 	 	 	 	 39.2
Mild c       32.4
a reported severity of adverse events from 8 to 10 on a scale from 0 to 10 
b	reported	severity	of	adverse	events	from	3	to	7	on	a	scale	from	0	to	10
c reported severity of adverse events from 0 to 2 on a scale from 0 to 10  
One case of potentially permanent side 
effects was reported. A woman with mi-
graine with aura belonging to a FHM 
family reported a severe migraine-like 
headache without aura symptoms, 
which she treated with 10 mg rizatrip-
tan. She ended up in a central hospital 
due to walking difficulties, dizziness, 
ataxia, mild right side hemiparesis and 
visual disturbances.  The hemiparesis 
persisted despite completely normal 
neuroradiological evaluations (brain 
MRI, brain MRI with cadolinium, 
MRA, cervical MRI and Doppler ultra-
sound of carotid vessels). After three 
months, azetazolamide treatment was 
started with the dramatic response of 
the reoccurrence of the symptoms. The 
patient continues to have occasional 
HM attacks. A follow-up MRI with 3T 
equipment was normal 6 years after 
the incident.
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DISCUSSION
The data presented support the idea 
that migraine is a complex disease. 
Migraine has many faces, phenotypes, 
and sometimes it looks like each pa-
tient has migraine of her own. There-
fore, the nature and genetic back-
ground of migraine has been difficult 
to resolve. One possible tool has been 
to evaluate the comorbidity of mi-
graine. Many kinds of comorbidities 
have been suggested during past de-
cades, but they have been either vague 
or have not led us nearer to origins of 
migraine. Results of this study high-
light the complex neurovascular na-
ture of migraine and contribute to the 
knowledge regarding neuronal, vascu-
lar, immunological and psychological 
aspects of migraine. Subjects suffer-
ing from migraine in the FMGP have 
an elevated risk for hypotension, aller-
gy and psychiatric disorders and men 
who suffer from MA are more likely 
to have epilepsy and IS. Subjects with 
CAD have a higher prevalence of mi-
graine than healthy controls and alle-
viation of migraine after CAD further 
indicates the association of these two 
conditions. Therefore, it seems likely 
that CAD is an important link between 
MA and IS. Overall, associations were 
especially evident with subjects with 
migraine aura or aura-like symptoms 
suggesting that the aura phase plays 
an important role in the comorbidity of 
migraine. Significant evidence of link-
age was found between visual migraine 
aura and the chromosomal region 
9q21–q22, a known occipitotemporal 
lobe epilepsy locus (241). It seems that 
triptans are safe and effective in the 
treatment of hemiplegic migraine.
   Results of this study are con-
sistent with numerous previous publi-
cations. In the studied population, al-
lergy and psychiatric conditions were 
comorbid with migraine as previously 
reported (242-244). In a more detailed 
analysis, the disorders were especially 
prevalent with the phenotypes includ-
ing aura (MA, MA+MO and UNC). 
Subjects belonging in category HA 
seem to have a trend comorbidities in 
similar fashion like migraineurs. This 
is understandable, as their headache 
might include some migraine features. 
However, not any of the comorbidities 
was significantly different from sub-
jects without headache. The relation-
ship between blood pressure and mi-
graine has been controversial. Most of 
the studies that show association be-
tween hypertension and migraine have 
been done before the introduction of 
the ICHD. However, the most recent 
studies have associated migraine to hy-
potension (189, 190). 
 Prior studies have shown a 
clear association between migraine 
and epilepsy (196) and the link with 
epilepsy has been especially strong 
with MA (200). Several antiepilep-
tic agents are effective in treatment of 
migraine (107, 110). Migraine and ep-
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ilepsy are both episodic disorders as-
sociated with cortical hyperexcitabil-
ity. In the present study, epilepsy was 
significantly associated with migraine 
among men only. Beyond clinical and 
epidemiological association, migraine 
and epilepsy partly share a common 
genetic background. All three known 
FHM genes (CACNA1A, ATP1A2 and 
SCN1A) (8-10) have also been associ-
ated to epileptic seizures (41, 42). We 
found significant evidence of linkage 
between visual migraine aura and the 
chromosomal region 9q21–q22. This 
region stands out among other identi-
fied migraine loci because it had previ-
ously been linked to occipitotemporal 
lobe epilepsy in a Belgian family (241). 
The highest parametric linkage signal 
was detected when all subjects with 
aura were considered affected. The sig-
nal at this locus decreased when pure 
MA end-diagnosis or migraine head-
ache were used as a selection criteria. 
The difference in Lod Scores suggests 
a direct link between this locus and the 
aura mechanisms. 
 Migraine and epilepsy can 
both be divided into several subgroups. 
These subgroups seem to differ in their 
pathophysiology and genetic back-
ground, but the shared mechanisms 
of migraine and epilepsy seem to ex-
ist only in certain of these subgroups. 
This means that a detailed analysis of 
the phenotypes, both in migraine and 
epilepsy, is the key for further studies. 
Careful analysis of the migraine aura, 
whether it includes hemiplegic, visual, 
sensory or speech symptoms, seems to 
be important (fig 10).
 
Figure 10. Association of epilepsy and migraine and their subgroups.    
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The association of migraine and stroke 
is well established (146, 147). How-
ever, in our consecutive families from 
the FMGP, the only significant finding 
was that men who fulfilled the crite-
ria of both migraine with and without 
aura had an elevated risk for stroke. 
Association of migraine and stroke 
has been reported more convincingly 
in women than in men (132). Interest-
ingly, the only previous exception to 
the rule so far has been another Finn-
ish study (137). Therefore, it is possible 
that a shared genetic liability to these 
conditions is stronger in males in the 
Finnish population. Several clinical 
conditions have been suggested to con-
tribute to the link between stroke and 
MA, but none of them alone are likely 
to explain the whole phenomenon (Fig. 
11). Complicated migraine attacks rare-
ly induce IS, an event called migrain-
ous infarction (MI), which is probably 
a consequence of prolonged oligemia 
induced by CSD. However, CSD alone 
does not explain the association be-
tween migraine and ischemia, because 
even though its link to stroke is under-
standable, the connection with isch-
emic heart disease is more difficult to 
explain. Subjects with MA have been 
reported to have an increased preva-
lence of PFO (152), which is associat-
ed to IS (155). Subjects with migraine 
have been reported to have more tra-
ditional vascular risk-factors than sub-
jects without migraine (193). Howev-
er, migraine has not been associated 
to atherosclerosis in carotid vessels 
(245). An interesting connection be-
tween IS and migraine is CAD, which 
is known in the etiology of stroke and 
plays an especially important role in 
young stroke patients (164). CAD and 
migraine have been linked in a small 
series (166), but to the best of our 
knowledge, our report is the first study 
to show the connection between CAD 
and MA. 
 
PFO=Patent Foramen Ovale
CAD=Cervical Artery Dissection
MI=Migrainous Infarction
Figure 11. Illustration of associations between migraine with aura and ischemic stroke.
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Increased knowledge of the comorbid-
ity might be helpful in designing indi-
vidual treatment strategies for subjects 
suffering from migraine. It seems that 
the comorbidity of migraine is espe-
cially evident and important among 
subjects with aura. Migraine seems to 
be associated to both neuronal (epilep-
sy) and vascular (IS, CAD) syndromes, 
thereby suggesting the importance of 
both of these phenomena in the patho-
physiology of migraine.
 There are several implications 
of the data when migraine pathophys-
iology and treatment are considered. 
Prophylaxis of stroke is important in 
familial migraine. Treatment of aller-
gic conditions is important and could 
also cause migraine relief. Treatment 
of psychiatric conditions, especially 
depression, is an essential part of com-
prehensive migraine care. Antiepi-
leptic medications could be especially 
good choices for migraine prophylaxis 
if there is a family history of comor-
bid epilepsy. From a pathophysiologi-
cal point of view, studies involving ion 
channels (epilepsy), vascular systems 
(hypotension, IS and CAD), immunol-
ogy (allergy) and serotonergic trans-
mission (psychiatric conditions) are 
indicated. Besides therapeutical impli-
cations, this may be important when 
searching for the elusive genes caus-
ing the common forms of migraine. 
A locus for both migraine and epilep-
sy on chromosome 9q suggests a ma-
jor target for further molecular genetic 
studies. Migraine families can be cat-
egorized based on their familial co-
morbidities and the resulting catego-
ries studied separately. This will, most 
probably, lead to more homogenous 
study populations, and increase the 
likelihood that current molecular ge-
netic methods will locate new migraine 
genes increases. 
 Migraine pathophysiology in-
volves dysfunction in both neuronal 
and vascular systems, but in recent 
years the focus has generally been on 
the neuronal system. Our results asso-
ciating migraine to an arterial disorder 
suggest that vascular system phenom-
ena should not be overlooked. There 
is reasonable evidence indicating that 
both migraine and CAD are multifac-
torial diseases with genetic predisposi-
tion (246). As PFO and CAD are linked 
to migraine, all the conditions might 
represent inherited disturbance of vas-
cular endothelin function and explain 
the comorbidity. CAD patients may 
have a constitutional, genetically deter-
mined weakness of the vessel wall, and 
environmental factors, such as acute 
infection or minor trauma, could act 
as triggers. It remains to be elucidated 
whether a mutual arterial pathophysi-
ology shared by CAD and migraine, or 
simply a concomitant inherited sus-
pectibility, exists. The reported allevi-
ation of migraine after CAD supports 
the hypothesis of some causal relation-
ship between these diseases. It seems, 
that alleviation of migraine was linked 
to CAD independently from IS. The 
role of CAD and IS treatments, such as 
63
anticoagulants and antihypertensive 
medications, remain unclear. 
 Subjects with HM have been 
excluded from all prior triptan studies 
(53). Our study demonstrates that trip-
tans are effective for most of the HM 
patients. Several adverse events were 
reported, but almost all of them were 
transient and were either the result of 
typical triptan side effects (thoracic 
pain, nausea and fatigue) or the symp-
toms of normal migraine attacks. One 
patient reported alarming long lasting 
symptoms: mild hemiparesis, ataxia, 
walking difficulties, dizziness and vi-
sual disturbances for several months. 
However, a stroke seems unlikely, be-
cause none of the several MRI stud-
ies demonstarted ischemic signs or 
any other pathology. Most likely, the 
patient had an unusually long lasting 
attack of HM. Therefore, the role of 
rizatriptan remains unclear, but it is 
possible that it either induced or en-
hanced these symptoms. Triptans seem 
to be safe in the treatment of FHM, but 
they should be used with caution. Trip-
tans work for both FHM and migraine 
without aura suggesting that the disor-
ders are part of a common spectrum.
 Some reservations are appro-
priate when analyzing the presented 
data. The applied questionnaire, the 
FMSQFS (236), has been validated 
for migraine but not for the associated 
diseases. The studied populations are 
clinical or family-based, they are not 
population-based samples. Therefore, 
as results of the study can not be gen-
eralized straightforwardly and precise 
incidence or prevalence figures cannot 
be drawn from the data, the focus has 
to be placed on the reported differenc-
es between the studied groups. Analy-
sis of migraine aura with the question-
naire can be criticized as a too robust 
method for such a delicate phenom-
enon. However, possible problems 
should be similar in all studied groups. 
The nature of the possible aura was as-
sessed in several different ways by the 
FMSQFS and in many cases clinical 
features were re-evaluated in a tele-
phone interview. Self-reporting of co-
existing conditions is also problematic. 
Especially in conditions such as psychi-
atric disorders, laboratory parameters 
and blood pressure. We are aware of 
the short comings of these results with 
respect to its validity. When analyzing 
blood pressure of a individual from a 
questionnaire, it is impossible to know 
whether the reported result is based in 
perhaps only one, and therefore unreli-
able measurement. On the other hand 
self-reporting should be relatively reli-
able in conditions such as epilepsy, al-
lergy, asthma, stroke. 
 One of the limitations of the 
family-based linkage method is that 
the linked region is typically large, har-
boring dozens of genes. A case-control 
association study targeted to the linked 
9q21-q22 region might provide a bet-
ter resolution. However, a large sample 
size with similar phenotype, i.e. scintil-
lating scotoma, is not currently avail-
able, but might be possible to achieve 
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with international collaboration. Addi-
tionally, a proportion of men was too 
small for a reliable sex-specific linkage 
analysis.
 The prevalence of migraine 
has been generally estimated to be 10 
to 12%, but higher numbers of lifetime 
prevalence have also been reported 
(23, 247). In study III, the prevalence of 
migraine was exceptionally high, up to 
22% in control group. No population-
based studies of migraine prevalence 
in Finland exist, but prevalence is like-
ly comparable to that in other North-
ern European countries (248). Con-
trols were recruited randomly with the 
help of the Finnish Population Regis-
ter Center and interviewed by a study-
neurologist as a part of a larger study, 
not focused on migraine. Therefore, 
possibility of a bias should have been 
minimized. Importantly, patients suf-
fering from CAD still had significantly 
more migraine regardless of the high 
prevalence numbers in the controls.
 The chosen retrospective set-
ting in study IV is not optimal, but it 
would not be possible or even ethical 
to carry out a prospective study with 
a compound that is contraindicated 
in the study population. It can also be 
argued that it would be optimal if the 
diagnosis of HM were based on mo-
lecular genetic data. While this would 
naturally add value to our study, in 
most instances this would be very diffi-
cult and our neurologist-based diagno-
ses reflect the real-life clinical situation 
and are in accordance with the current 
ICHD-II criteria (2).
 A novel techniques, such as 
GWA, will hopefully shed light to ge-
netics and basic mechanisms of mi-
graine. Our recent GWAs in MA pa-
tients identified a sequence variant on 
chromosome 8q with significant as-
sociation to migraine with aura (Ant-
tila et al., submitted). The expression 
quantitative trait study in lymphoblas-
toid cell lines showed a strong correla-
tion between the variant and transcript 
level of a nearby downstream gene, 
that has long been suspected to play a 
key role in migraine pathophysiology 
through glutamate-mediated neuronal 
hyperexcitability (249). The results of 
the meta-analysis strongly suggest the 
existence of a shared underlying mech-
anism for the two main forms of mi-
graine (MA and MO). However, it will 
be important in the future studies that 
migraine is phenotyped as accurately 
as possible. This has turned out suc-
cessful in genetic studies of migraine 
(50) and similar efforts are needed in 
clinical and therapeutic studies. It will 
be important to figure out individu-
ally what kind of medications are best 
for certain patient and to know better 
which patients are in major risk for se-
rious complications, such as ischemic 
stroke or chronification of migraine.     
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CONCLUDING REMARKS
 
Careful analysis of migraine comorbid-
ity is one of the possible clinical strat-
egies to subgroup migraine population 
for further analysis. Vascular, immu-
nological and psychiatric aspects are 
all important. Epilepsy and stroke are 
very important comorbidities, but their 
prevalence in the migraine population 
depends heavily on the target popula-
tion (migraine families, aura families, 
population-based studies). Sometimes 
a vascular pathology can be a provok-
ing factor for migraine, or at least it 
may cause an increase in migraine fre-
quency. Triptans work in the headache 
phase of all subgroups of migraine 
(MO, MA and FHM), suggesting that 
the various migraine subgroups have 
similar pathophysiological mecha-
nisms during the headache phase. The 
aura seems to differ more between var-
ious subgroups of migraine, perhaps 
creating an important tool for better 
phenotyping of migraine patients. This 
has consequences on genetic, epide-
miological and even clinical studies of 
migraine. Migraine phenotypes and 
migraine comorbidity are complex. 
However, it seems that these complexi-
ties have to be taken into consideration 
before the pathophysiology of migraine 
can be made simple.
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